NZ619298B2 - Hcv genotype 3 replicons - Google Patents
Hcv genotype 3 replicons Download PDFInfo
- Publication number
- NZ619298B2 NZ619298B2 NZ619298A NZ61929812A NZ619298B2 NZ 619298 B2 NZ619298 B2 NZ 619298B2 NZ 619298 A NZ619298 A NZ 619298A NZ 61929812 A NZ61929812 A NZ 61929812A NZ 619298 B2 NZ619298 B2 NZ 619298B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- rna
- genotype
- hcv
- cell
- replicon
- Prior art date
Links
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims abstract description 144
- 230000035772 mutation Effects 0.000 claims abstract description 118
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims abstract description 26
- 101800001020 Non-structural protein 4A Proteins 0.000 claims abstract description 21
- 230000003612 virological Effects 0.000 claims abstract description 21
- 101800001019 Non-structural protein 4B Proteins 0.000 claims abstract description 17
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 12
- 102200108303 TP53 P89L Human genes 0.000 claims abstract 5
- 101710026336 S5 Proteins 0.000 claims abstract 3
- 101710033766 Segment-10 Proteins 0.000 claims abstract 3
- 210000004027 cells Anatomy 0.000 claims description 276
- 230000000694 effects Effects 0.000 claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 239000005089 Luciferase Substances 0.000 claims description 37
- 108060001084 Luciferase family Proteins 0.000 claims description 37
- 229920000023 polynucleotide Polymers 0.000 claims description 35
- 239000002157 polynucleotide Substances 0.000 claims description 35
- 108090001123 antibodies Proteins 0.000 claims description 34
- 102000004965 antibodies Human genes 0.000 claims description 34
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 28
- 108091005771 Peptidases Proteins 0.000 claims description 23
- 239000004365 Protease Substances 0.000 claims description 23
- 239000006166 lysate Substances 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 102200027697 PGM1 Q41R Human genes 0.000 claims description 7
- 210000004962 mammalian cells Anatomy 0.000 claims description 4
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 3
- 102100011960 MIR7-3HG Human genes 0.000 claims description 3
- 101710008473 MIR7-3HG Proteins 0.000 claims description 3
- 102000030951 Phosphotransferases Human genes 0.000 claims description 2
- 108091000081 Phosphotransferases Proteins 0.000 claims description 2
- HGMITUYOCPPQLE-UHFFFAOYSA-N 3-Quinuclidinyl benzilate Chemical compound C1N(CC2)CCC2C1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HGMITUYOCPPQLE-UHFFFAOYSA-N 0.000 claims 1
- 102000033147 ERVK-25 Human genes 0.000 claims 1
- 230000003044 adaptive Effects 0.000 abstract description 47
- 101800001014 Non-structural protein 5A Proteins 0.000 abstract description 35
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 abstract description 21
- 241000711549 Hepacivirus C Species 0.000 description 162
- 230000002401 inhibitory effect Effects 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 41
- 239000003112 inhibitor Substances 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 23
- 102000033180 ERVK-6 Human genes 0.000 description 22
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 238000010790 dilution Methods 0.000 description 15
- 101710036448 neo Proteins 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000000840 anti-viral Effects 0.000 description 14
- 238000004166 bioassay Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drugs Drugs 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 229920002092 cellular RNA Polymers 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000002609 media Substances 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 241000710188 Encephalomyocarditis virus Species 0.000 description 11
- 230000003362 replicative Effects 0.000 description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
- 229920001850 Nucleic acid sequence Polymers 0.000 description 10
- 102000011587 Polyproteins Human genes 0.000 description 10
- 108010076039 Polyproteins Proteins 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000001413 cellular Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002741 site-directed mutagenesis Methods 0.000 description 9
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 230000002068 genetic Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 229960001153 serine Drugs 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 241000242739 Renilla Species 0.000 description 7
- 239000003443 antiviral agent Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 229960003136 leucine Drugs 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 229960000310 ISOLEUCINE Drugs 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 108020004999 Messenger RNA Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 201000009910 diseases by infectious agent Diseases 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 229920002106 messenger RNA Polymers 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 101710036216 ATEG_03556 Proteins 0.000 description 5
- 229920002676 Complementary DNA Polymers 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 5
- 210000004940 Nucleus Anatomy 0.000 description 5
- 101710003000 ORF1/ORF2 Proteins 0.000 description 5
- 101700030467 Pol Proteins 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 5
- 229960000517 boceprevir Drugs 0.000 description 5
- 230000000295 complement Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000007876 drug discovery Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000000670 limiting Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 101710004466 rgy Proteins 0.000 description 5
- 101710030364 rgy1 Proteins 0.000 description 5
- 101710030359 rgy2 Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 5
- 210000001519 tissues Anatomy 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- -1 DNA or RNA Chemical class 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010025815 Kanamycin Kinase Proteins 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 229960000329 Ribavirin Drugs 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 210000003813 Thumb Anatomy 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010192 crystallographic characterization Methods 0.000 description 4
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 108010045030 monoclonal antibodies Proteins 0.000 description 4
- 102000005614 monoclonal antibodies Human genes 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000003389 potentiating Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229960002935 telaprevir Drugs 0.000 description 4
- 108010017101 telaprevir Proteins 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229960002898 threonine Drugs 0.000 description 4
- 238000003146 transient transfection Methods 0.000 description 4
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 3
- WTDWVLJJJOTABN-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=CC(N(CCO)S(C)(=O)=O)=C1C1CC1 WTDWVLJJJOTABN-UHFFFAOYSA-N 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N Bisbenzimide Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 229960002433 Cysteine Drugs 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229940109526 Ery Drugs 0.000 description 3
- 229960002989 Glutamic Acid Drugs 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 241001045988 Neogene Species 0.000 description 3
- 229920000750 Rapid DNA Polymers 0.000 description 3
- 229940014598 TAC Drugs 0.000 description 3
- 229920000401 Three prime untranslated region Polymers 0.000 description 3
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 3
- 229940121357 antivirals Drugs 0.000 description 3
- 230000001809 detectable Effects 0.000 description 3
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 3
- 230000003287 optical Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 229940026754 topical Antivirals Drugs 0.000 description 3
- 230000001052 transient Effects 0.000 description 3
- 238000004450 types of analysis Methods 0.000 description 3
- SLVAPEZTBDBAPI-GDLZYMKVSA-N (2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one Chemical compound CCC1=NC(CC)=CC(CC[C@]2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 SLVAPEZTBDBAPI-GDLZYMKVSA-N 0.000 description 2
- PASOFFRBGIVJET-YRKGHMEHSA-N (2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PASOFFRBGIVJET-YRKGHMEHSA-N 0.000 description 2
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102200002440 BNIP3L N84A Human genes 0.000 description 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 2
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- 208000006154 Chronic Hepatitis C Diseases 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 229950011045 Filibuvir Drugs 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000003463 Organelles Anatomy 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229960002429 Proline Drugs 0.000 description 2
- 101700028023 RALA Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010090287 SCY-635 Proteins 0.000 description 2
- 108020004459 Small Interfering RNA Proteins 0.000 description 2
- 229920000978 Start codon Polymers 0.000 description 2
- 229960005322 Streptomycin Drugs 0.000 description 2
- 229940113082 Thymine Drugs 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 230000003190 augmentative Effects 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000644 propagated Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 101700029718 ral Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002924 silencing RNA Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960003767 Alanine Drugs 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 108060001895 CRIPT Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 229940104302 Cytosine Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 210000004292 Cytoskeleton Anatomy 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 101710038044 ERVK-6 Proteins 0.000 description 1
- 101710027967 ERVW-1 Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920000665 Exon Polymers 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229960002885 Histidine Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100008763 IFNA2 Human genes 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UWTATZPHSA-N L-Asparagine Natural products OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101700038420 MVP Proteins 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- 241000581002 Murex Species 0.000 description 1
- 101700064960 NS-5 Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102100017263 PSMD4 Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229940002988 Pegasys Drugs 0.000 description 1
- 229940106366 Pegintron Drugs 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 229920000582 Polyisocyanurate Polymers 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108060006943 RdRp Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920001914 Ribonucleotide Polymers 0.000 description 1
- 101700022912 S7 Proteins 0.000 description 1
- 101710042981 SHMT1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 101710023234 Segment 5 Proteins 0.000 description 1
- 101710026330 Segment-11 Proteins 0.000 description 1
- 101710026339 Segment-12 Proteins 0.000 description 1
- 101710043164 Segment-4 Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241001243925 Sia Species 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N Triadimefon Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- 101700021629 VEMP Proteins 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- 229940093612 Zein Drugs 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- ASCUXPQGEXGEMJ-GPLGTHOPSA-N [(2R,3S,4S,5R,6S)-3,4,5-triacetyloxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(4-methylanilino)oxan-2-yl]methoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]1OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](NC=2C=CC(C)=CC=2)O1 ASCUXPQGEXGEMJ-GPLGTHOPSA-N 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 101710030587 ligN Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 101700077585 ligd Proteins 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 150000002894 organic compounds Chemical group 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000001711 protein immunostaining Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000001296 salvia officinalis l. Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24231—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24241—Use of virus, viral particle or viral elements as a vector
- C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/186—Hepatitis C; Hepatitis NANB
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/9506—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from viruses
- G01N2333/9513—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from viruses derived from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
Disclosed is a genotype 3a hepatitis C viral (HCV) RNA construct comprising a S 'NTR, an internal ribosome entry site (IRES), sequences encoding NS3 and one or more ofNS4A, NS4B, NSSA or NSSB, and a 3 'NTR, wherein the RNA construct further comprises a mutation, as compared to a wild-type HCV 3a sequence, wherein the mutation is selected from N607S or P89L or both in NS3. Also disclosed is the above mentioned RNA construct wherein the construct comprises an adaptive mutation in NS3, NS4A, NS4B, NS5A or NS5B as compared to the wildtype. uence, wherein the mutation is selected from N607S or P89L or both in NS3. Also disclosed is the above mentioned RNA construct wherein the construct comprises an adaptive mutation in NS3, NS4A, NS4B, NS5A or NS5B as compared to the wildtype.
Description
HCV GENOTYPE 3 REPLICONS
CROSS REFERENCE TO RELATED APPLICATIONS
This ation claims the benefit under 35 U.S.C. § 119(6) of United States
ional Applications Serial Number 61/504,853 filed July 6, 2011 and Serial Number
,989 filed July 20, 2011, the content of each of which is incorporated by reference in its
entirety into the present disclosure.
FIELD OF THE DISCLOSURE
The sure is directed to hepatitis C replicons of genotype 3 and methods of
preparing and using the replicons.
STATE OF THE ART
[0002a] nce to any prior art in the specification is not, and should not be taken as, an
acknowledgment or any form of suggestion that this prior art forms part of the common general
knowledge in New Zealand or any other jurisdiction.
Chronic hepatitis C virus (HCV) ion remains a significant global heath burden
with an ted 160 million people ed world-wide. The current standard of care is 24 to
48 week courses of pegylated interferon plus ribavirin. Due to the partial efficacy and poor
tolerability of this regimen, the discovery and pment of new antiviral agents has been
intensely d. Recently, these efforts have culminated in the FDA approval of two NS3
protease inhibitors (boceprevir and telaprevir) for use in combination with pegylated eron
and ribavirin for the treatment of chronic genotype 1 HCV infection. Many other inhibitors are in
advanced clinical development, however, the majority are being developed to treat genotype 1
infections.
HCV is a positive-strand RNA virus that exhibits extraordinary genetic diversity. Six
major genotypes (i. e. genotype 1-6) along with multiple subtypes (e. g. genotype la, lb, 10 etc.)
have been reported. Genotypes 1, 2 and 3 have worldwide distributions. Genotypes la or lb are
generally predominant in North America, South America, Europe and Asia. However, genotypes
2 and 3 are common and can constitute 20 to 50% of infections in many of these areas. Genotype
4a is the predominant in the Middle East and many African countries; up to 15% of the
population of Egypt is infected with HCV and 93% of infections are genotype 4. Genotype 5 is
prevalent in South Africa, while Genotype 6 is most common in Asia. Although most continents
and countries have a ant” pe, infected populations are almost universally made up
of a mixture of multiple genotypes. Furthermore, the geographical distribution and diversity
(epidemiology) of HCV infection is continuously evolving, due to large-scale
ation and widespread intravenous drug use. For instance, genotype 4a has
noticeably spread into l and northern Europe. This presents a clinical challenge,
since it is well documented that individual genotypes respond differently to both direct
antivirals and immunomodulatory therapies, including the current standard of care.
HCV replicons are self-replicating RNA sequences d from the HCV
genome and have served as workhorses both for molecular virology studies and drug
discovery. To date, replicons have been ished from two genotypes and three
subtypes (genotypes la, l b and 2a). These replicons have been l in multiple aspects
of drug ery and development including the identification of novel inhibitor classes,
the optimization of al candidates and the characterization of clinical resistance.
Recently, there has been increasing interest in developing next-generation drugs that are
active against all major HCV genotypes. y, the approval of "pan-genotypic" drugs
and regimens will greatly simplify the treatment of HCV.
A key step in the pursuit of pan-genotypic treatment regimens will be the
development of in vitro tools that allow the study of all major genotypes and subtypes.
Replicons derived from sequences of additional major genotypes {i.e. those other than
genotype la, lb or 2a), however, have not been generated. In ular, despite the
worldwide prevalence of genotype 3 HCV in the Middle East, North Africa and Europe,
no genotype 3 replicons have been described.
SUMMARY
It has been discovered, unexpectedly, that clonal cell lines stably replicating
genotype 3 replicons were obtained by transcribing and electroporating subgenomic
genotype 3 cDNAs into HCV permissive cell lines. Adaptive mutations have been
identified from these clones, as compared to the wildtype virus. When these mutations
were engineered by site-directed mutagenesis and introduced into the cell lines, HCV
genotype 3 ations ensued. One such adaptive mutation is N607S at NS3 and another
such adaptive mutation is P89L at NS3. The establishment of a robust genotype 3
replicon system provides ul tools to tate drug discovery and pment
efforts.
1001321151
Accordingly, one embodiment of the present disclosure provides a genotype 3 hepatitis
C Viral (HCV) RNA construct that is capable of replication in a eukaryotic cell, wherein the
RNA sequence comprises a S’NTR, an internal ribosome entry site (IRES), sequences encoding
one or more ofNS3, NS4A, NS4B, NSSA or NSSB, and a 3’NTR.
In one aspect, the uct comprises an adaptive mutation in N83, NS4A, NS4B,
NSSA or NSSB. In another aspect, the mutation ses an isoleucine at location 2204
(residue 232 in NSSA). In yet another aspect, the mutation comprises, in N83, a serine at residue
607.
In yet another aspect, the mutation comprises, in N83, a leucine at residue 89. In some
aspects, the mutation further comprises one or more of an arginine at residue 41, a threonine at
residue 166, a ine at e 379, a glycine at residue 534, a glutamic acid at residue 583,
and/or a cysteine at residue 1. In yet another aspect, the mutation further comprises one of more
provided in Tables 7-9.
Moreover, DNA that transcribes to the RNA construct, Viral particles that include the
RNA construct, and cells ning such DNA or RNA are also provided.
Also provided, in another embodiment, is an NS3 protein ofHCV genotype 3 that
comprises a serine at residue 607 and/or a leucine at residue 89. In another ment,
provided is an NSSA n that comprises an isoleucine at location 2204 ue 232 in
NSSA). cleotides encoding these proteins and antibodies that specifically recognize the
proteins are also provided.
In another embodiment, the t disclosure provides an isolated cell comprising a
genotype 3 hepatitis C viral (HCV) RNA that replicates in the cell. In one , there is an
absence, in the cell, of a DNA construct encoding the RNA. In r aspect, the cell comprises
at least 10 copies, or alternatively at least about 100, 500, 1000, 2000, 5000, 10,000, 1 x 105, l X
106, 1 x 107, 1 X 108 or 1 x 109 copies of the RNA. In any of such aspects, the RNA can be a
subgenomic HCV sequence or a full-length HCV sequence and can include one or more of the
adaptive mutations described above.
Methods of improving the capability of a genotype 3 HCV viral RNA to ate in a
eukaryotic cell are also provided, comprising substituting residue 607 ofN83 with a serine
and/or substituting residue 89 ofN83 with a leucine. Further mutations can include one of more
1001321151
of an arginine at residue 41, a threonine at residue 166, a threonine at residue 379, a glycine at
residue 534, a glutamic acid at residue 583, and/or a cysteine at residue 1 or those provided in
Tables 7-9.
Still provided, in one embodiment, is a method of identifying an agent that inhibits the
replication or activity of a pe 3 HCV, sing contacting a cell of any of the above
embodiments with a ate agent, wherein a decrease of replication or a decrease of the
activity of a protein encoded by the R A indicates that the agent inhibits the replication or
activity of the HCV. Alternatively, the method comprises contacting the lysate of a cell of any of
the above embodiments with a candidate agent, wherein a decrease of the activity of a protein
encoded by the RNA indicates that the agent inhibits the activity of the HCV.
BRIEF DESCRIPTION OF THE DRAWINGS
The disclosure is best understood from the following detailed description when read in
conjunction with the accompanying drawings. Included in the drawings are the following
figures:
is a schematic diagram of genotype 3a replicon constructs. An 852 3a strain
(Accession #: GU814264) replicon encodes a neomycin (A) or a Renilla rase (Rluc)—
neomycin fusion reporter (B). The synthesized replicon incorporated the following elements
from 5’ to 3’: the 852 5’UTR; the neomycin otransferase II gene (neo) or Rluc-Neo gene;
the alomyocarditis virus (EMCY) IRES; the N83 ~NSSB polyprotein region of 852
including an N85 A ve mutation (822041) and the 3’UTR of 852. Solid boxes indicate
HCV core sequence. Dot shaded boxes indicate the HCV polyprotein sequence. “+” indicates the
822041 adaptive mutation. The 5’ and 3’ non—translated s (NTR), and EMCV IRES are
indicated.
[0018] presents data to show that the GT3a replicon N83 protease ties in
se to exposure to an N83 protease inhibitor Compound C. 1 x 105 GT3a replicon cells
were pelleted and lysed in 2.4 ml 1 x Promega rase lysis buffer supplemented with 150
mM NaCl at room temperature for 15 min. The cell lysate was then distributed to a l
plate with a volume of 80 ul per well. Antiviral drug dilutions were prepared in DMSO at 10
times the final desired concentrations (5 nM or 50 nM). Portions (10 1.11) of diluted
Compound C was then added to each well of cell lysates, and the plates were
incubated on a plate shaker for 10 minutes at room temperature. Then, 10 mΐ of 1 mM
europium-labeled NS3 substrate was added to each well. Protease activity data were
collected and the data were presented as the percentage of inhibition of DMSO l.
shows robust NS5A expression in genotype 3a replicon cell line. Stable
GT3a, GTla, GTlb and GT2a replicon cells and 1C cells, 0.5 x 106 each were ed
and completely lysed in 100 mΐ SDS loading buffer. Twelve microliter lysates were
subjected to SOS-PAGE and Western blot analysis. The blot was stained with primary
anti-NS5A antibody (Apath; 1:3000 dilution) and secondary anti-mouse antibody (IRDye
800CW Goat anti-Mouse IgG (H + L) from , 1:10,000 dilution). The ng was
then analyzed by Odyssey Imaging (LI-COR, Lincoln, Nebraska). The blot was also co-
stained with anti-BiP antibody (Abeam, 1:1000 dilution) and secondary anti-rabbit
antibody (IRDye 800CW Goat anti-Rabbit IgG (H + L) from LI-COR, 00 dilution)
as a loading control. 1C cells were included as a negative control. Strong expression of
NS5A was detected in the pe 3a replicon cell clone, confirming that these cells
stably and ly replicate this replicon.
-C show a schematic diagram of genotype 3a replicon constructs in
Example 3 . Genotype 3a S52 strain replicons encode a neomycin phosphotransferase II
gene (neo) (A), a Renilla luciferase (Rluc)-neo fusion reporter (B) or a Pi a
luciferase (PiRluc) fusion reporter (C). The synthesized replicon incorporated following
elements from 5'to 3': the S52 5TJTR; the Neo, Rluc-neo or Pi-Rluc reporter gene; the
EMCV IRES; the NS3 - NS5B polyprotein region of S52 ing an NS5A adaptive
mutation (S2210I) and the 3TJTR of S52. - indicates HCV S52 core sequence.
indicates HCV polyprotein sequence. " " indicates the S2210I adaptive mutation.
The 5'and translated s (NTR) and EMCV IRES are indicated.
-B show NS5A expression in selected genotype 3a replicon cells. (A).
NS5A expression in selected replicon cells. The two stable genotype 3a replicon clones,
as well as the genotype l b replicon cells, were ed and completely lysed in SDS
loading buffer. Lysates were then subjected to SDS-PAGE and Western blot is.
The blot was stained with primary anti-NS5A antibody (Apath; 1:3000 dilution) and
secondary anti-mouse antibody (IRDye 800CW Goat anti-Mouse IgG (H + L) from LI-
COR, 1:10,000 dilution). The blot was also ined with anti-BiP antibody (Abeam,
1001321151
1:1000 dilution) and secondary anti—rabbit antibody (IRDye 680CW Goat anti-Rabbit IgG (H +
L) from LI-COR, 1210,000 dilution) as a loading control. The ng was analyzed by Odyssey
Imaging (LI-COR). (B). NSSA immunostaining of the selected replicon cells. The genotype 3a
replicon clone #1 was d with anti~NSSA antibody (red) and Hoechst 33342 (blue,
indicating nuclei). 1C cells were stained as a negative control.
shows that selected genotype 3 a replicon clone acquires adaptive ons.
Total cellular RNA was extracted from the genotype 3a replicon cell clone #1 and then
electroporated into Huh7-Lunet cells at the indicated amounts. Transfected cells were
resuspended in complete DMEM medium, plated in a 100-mm diameter dish, and ed with
0.5 mg/ml G418 (also known as Geneticin®, an aminoglycoside antibiotic). Three weeks later,
colony plates were fixed with 4% formaldehyde and stained with 0.05% crystal violet. In vitro-
transcribed GT3a replicon RNA was transfected in parallel as a control.
is a chart g the establishment of stable and robust GT3a Rluc-Neo
replicon cell lines. The P89L mutation in N83 was introduced into the GT3a 852 Rluc-neo
construct by site-directed mutagenesis. The GT3a—P89L—Rluc—neo mutant replicon RNA and the
parental GT3 neo replicon RNAs (10 ug each) were transfected into 1C or Huh7-Lunet
cells. The number of ing colonies was counted for each selection.
-B indicate Luciferase sion in genotype 3a luciferase cell clones. (A).
Selected genotype 3a replicon cell clones derived from 1C cells. (B). Selected pe 3a
replicon cell clones derived from Huh7—Lunet cells. Genotype la and genotype 1b stable replicon
cells were included as references. Untransfected 1C or Huh7—Lunet cells were ed as a
negative control. 60,000 cells were used for renilla rase ty assay.
shows that combined mutations P89L in N83 and 82321 in NSSA (822101)
enhanced genotype 3a replicon replication. Mutations P89L in N83 and double mutations P89L
in N83 and 82321 in NSSA were introduced into genotype 3a 852 PiRluc construct by site-
directed mutagenesis respectively. All replicon RNAs were transfected into 1C cells individually
and 1 x 104 transfected cells were plated into wells in a 96-well plate. At 4 hours, and day 1 to
day 7 post transfection, cells were analyzed for Renilla luciferase activity.
A-B present curves to show that the genotype 3 a cured cell lines are highly
permissive to genotype 3a replication. Pi-Rluc-GT3 a—P89L (A), Pi-Rluc—GTla and c-Gle
(B) on RNAs were transfected into 1C or genotype 3a cured cells. Luciferase activity was
100132115]
measured daily for 4 days post transfection. Two cured on cell lines, 3a—C2 and 3a-C3,
exhibited the highest degree of permissiveness to genotype 3 a ation.
A-B show that secondary mutations in N83 or NS4A enhanced genotype 3a
replicon replication. Secondary mutations Q41R, A166T, A3 79T, SS34G, K5 83E in N83, or
SIC, in NS4A were introduced into the GT3a-P89L PiRluc construct by site—directed
mutagenesis. Replicon RNAS (Pi-Rluc-Gle as a control) were individually transfected into 1C
(A) or 3a—C3 (B) cured cells, and 1 x 104 transfected cells were plated per well in a 96-well plate.
Cells were analyzed for a luciferase activity at 4 hours and daily for 7 days post
transfection. Data ted in the figure are from a representative experiment of at least two
independent experiments.
DETAILED DESCRIPTION
Prior to describing this disclosure in greater detail, the following terms will first be
defined.
[0029] It is to be tood that this disclosure is not limited to particular embodiments
described, as such may, of course, vary. It is also to be understood that the terminology used
herein is for the purpose of describing particular embodiments only, and is not intended to be
limiting, since the scope of the present disclosure will be limited only by the ed .
It must be noted that as used herein and in the appended claims, the singular forms (6 39
“an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for
e, reference to “a thread” includes a plurality of threads.
1. Definitions
Unless defined otherwise, all technical and scientific terms used herein have the
same meaning as commonly understood by one of ordinary skill in the art to which this
disclosure belongs. As used herein the following terms have the following meanings.
As used , the term "comprising" or "comprises" is intended to mean that
the compositions and methods include the recited elements, but not excluding others.
sting essentially of when used to define compositions and methods, shall mean
excluding other elements of any essential significance to the combination for the stated
e. Thus, a composition ting essentially of the elements as defined herein
would not exclude other materials or steps that do not materially affect the basic and
novel characteristic(s) of the claimed disclosure. "Consisting of shall mean excluding
more than trace elements of other ingredients and substantial method steps. ments
defined by each of these transition terms are within the scope of this disclosure.
The term "about" when used before a numerical designation, e.g., temperature,
time, amount, and concentration, including range, indicates approximations which may
vary by ( + ) or ( - ) 10 %, 5 % or 1 % .
The term "protein" and "polypeptide" are used interchangeably and in their
broadest sense to refer to a compound of two or more subunit amino acids, amino acid
s or peptidomimetics. The ts may be linked by peptide bonds. In another
embodiment, the subunit may be linked by other bonds, e.g. , ester, ether, etc. A protein or
peptide must contain at least two amino acids and no limitation is placed on the maximum
number of amino acids which may comprise a protein's or peptide's sequence. As used
herein the term "amino acid" refers to either natural and/or unnatural or synthetic amino
acids, including glycine and both the D and L optical isomers, amino acid analogs and
peptidomimetics. Single letter and three letter abbreviations of the naturally occurring
amino acids are listed below. A peptide of three or more amino acids is commonly called
an eptide if the peptide chain is short. If the peptide chain is long, the peptide is
commonly called a polypeptide or a protein.
M Met L-methionine
A Ala L-alanine
S Ser L-serine
I e L-isoleucine
L Leu L-leucine
T Thr L-threonine
V Val L-valine
P Pro L-proline
K Lys L-lysine
H His L-histidine
Q Gin L-glutamine
E Glu L-glutamic acid
W Trp L-tryptohan
R Arg L-arginine
D Asp rtic acid
N Asn L-asparagine
C Cys L-cysteine
The terms "polynucleotide" and nucleotide" are used interchangeably and
refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or
ribonucleotides or analogs thereof. Polynucleotides can have any three-dimensional
structure and may perform any function, known or unknown. The following are
non-limiting examples of polynucleotides: a gene or gene nt (for example, a probe,
primer, EST or SAGE tag), exons, introns, messenger RNA (mRNA), er RNA,
mal RNA, ribozymes, cDNA, inant polynucleotides, branched
cleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any
sequence, nucleic acid probes and primers. A polynucleotide can comprise modified
nucleotides, such as methylated nucleotides and nucleotide s. If present,
modifications to the nucleotide structure can be ed before or after assembly of the
polynucleotide. The sequence of nucleotides can be interrupted by non-nucleotide
components. A polynucleotide can be further modified after polymerization, such as by
conjugation with a labeling component. The term also refers to both double- and
single-stranded molecules. Unless otherwise specified or required, any embodiment of
this invention that is a polynucleotide encompasses both the -stranded form and
each of two complementary single-stranded forms known or predicted to make up the
double-stranded form.
A polynucleotide is composed of a specific sequence of four nucleotide bases:
e (A); cytosine (C); guanine (G); thymine (T); and uracil (U) for thymine when the
polynucleotide is R A. Thus, the term "polynucleotide sequence" is the alphabetical
representation of a polynucleotide molecule. This alphabetical representation can be
input into ses in a computer having a central processing unit and used for
bioinformatics applications such as functional genomics and homology searching.
"Homology" or "identity" or "similarity" refers to sequence rity between
two peptides or between two nucleic acid molecules. Homology can be determined by
comparing a on in each sequence which may be aligned for purposes of comparison.
When a position in the compared sequence is occupied by the same base or amino acid,
then the molecules are gous at that position. A degree of gy between
sequences is a function of the number of matching or gous positions shared by the
ces. An "unrelated" or "non-homologous" sequence shares less than 40% identity,
or alternatively less than 25% identity, with one of the sequences of the present invention.
In one embodiment, the homologous peptide is one that shares the same functional
characteristics as those described, including one or more of the adaptive mutations.
A polynucleotide or polynucleotide region (or a polypeptide or polypeptide
region) has a certain percentage (for example, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95% , 98%o or 99%) of "sequence identity" to another sequence means that, when aligned,
that percentage of bases (or amino acids) are the same in comparing the two sequences.
This alignment and the percent homology or sequence identity can be determined using
software programs known in the art, for example those described in l et al. eds.
(2007) Current Protocols in Molecular Biology. Preferably, default parameters are used
for alignment. One ent program is BLAST, using default parameters. In
particular, programs are BLASTN and BLASTP, using the following t parameters:
Genetic code = standard; filter = none; strand = both; cutoff = 60; expect = 10; Matrix =
BLOSUM62; Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = nonredundant
, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations +
SwissProtein + SPupdate + PIR. Details of these ms can be found at the following
Internet address: http://www.ncbi.nlm.nih.gov/blast/Blast.cgi, last accessed on July 15,
201 1. Biologically equivalent polynucleotides are those having the specified percent
gy and encoding a polypeptide having the same or similar biological activity.
The term "a homolog of a nucleic acid" refers to a nucleic acid having a
nucleotide sequence having a n degree of homology with the nucleotide sequence of
the nucleic acid or complement thereof. A homolog of a double stranded nucleic acid is
intended to include nucleic acids having a nucleotide sequence which has a certain degree
of homology with or with the complement thereof. In one aspect, homologs of nucleic
acids are e of hybridizing to the nucleic acid or complement thereof.
A "gene" refers to a polynucleotide containing at least one open reading frame
(ORF) that is capable of encoding a ular polypeptide or protein after being
transcribed and translated. Any of the polynucleotide or polypeptide sequences described
herein may be used to fy larger fragments or full-length coding sequences of the
gene with which they are associated. Methods of isolating larger fragment sequences are
known to those of skill in the art.
The term "express" refers to the production of a gene product.
As used herein, "expression" refers to the process by which polynucleotides are
transcribed into mRNA and/or the process by which the transcribed mRNA is
subsequently being translated into peptides, polypeptides, or proteins. If the
polynucleotide is derived from genomic DNA, expression may include splicing of the
mRNA in an otic cell.
The term "encode" as it is applied to polynucleotides refers to a polynucleotide
which is said to e" a polypeptide if, in its native state or when lated by
methods well known to those skilled in the art, it can be transcribed and/or translated to
produce the mRNA for the polypeptide and/or a fragment thereof. The antisense strand is
the complement of such a nucleic acid, and the encoding sequence can be deduced
therefrom.
"Eukaryotic cells" comprise all of the life ms except monera. They can
be easily distinguished through a ne-bound nucleus. Animals, plants, fungi, and
protists are eukaryotes or organisms whose cells are organized into complex ures by
al membranes and a cytoskeleton. The most characteristic membrane-bound
structure is the nucleus. A eukaryotic host, including, for example, yeast, higher plant,
insect and mammalian cells, or atively from a prokaryotic cells as described above.
Non-limiting examples include simian, bovine, porcine, murine, rats, avian, reptilian and
human.
As used herein, an "antibody" includes whole antibodies and any antigen
binding fragment or a single chain thereof. Thus the term "antibody" includes any protein
or peptide containing molecule that comprises at least a portion of an immunoglobulin
molecule. Examples of such include, but are not limited to a mentarity
determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a
heavy chain or light chain variable region, a heavy chain or light chain constant region, a
ork (FR) region, or any portion thereof, or at least one portion of a binding
protein. The antibodies can be polyclonal or monoclonal and can be isolated from any
suitable biological source, e.g., murine, rat, sheep and canine.
The terms "polyclonal antibody" or "polyclonal antibody composition" as used
herein refer to a preparation of antibodies that are derived from different B-cell lines.
They are a mixture of immunoglobulin molecules secreted against a specific antigen, each
recognizing a different e.
The terms "monoclonal antibody" or lonal antibody composition" as
used herein refer to a preparation of antibody les of single molecular composition.
A monoclonal antibody composition displays a single binding specificity and affinity for
a particular epitope.
The term "isolated" as used herein refers to molecules or biological or cellular
materials being substantially free from other materials or when referring to proteins or
polynucleotides, infers the breaking of covalent bonds to remove the protein or
polynucleotide from its native environment. In one aspect, the term ted" refers to
nucleic acid, such as DNA or RNA, or n or polypeptide, or cell or cellular organelle,
or tissue or organ, separated from other DNAs or RNAs, or proteins or polypeptides, or
cells or ar organelles, or s or organs, respectively, that are present in the
natural source. The term "isolated" also refers to a nucleic acid or peptide that is
substantially free of cellular material, viral al, or culture medium when produced by
recombinant DNA techniques, or chemical precursors or other chemicals when
chemically synthesized. Moreover, an "isolated c acid" is meant to include nucleic
acid fragments which are not naturally occurring as fragments and would not be found in
the l state. The term "isolated" is also used herein to refer to polypeptides which
are isolated from other cellular ns and is meant to encompass both ed and
recombinant polypeptides. In other embodiments, the term "isolated or recombinant"
means separated from constituents, cellular and otherwise, in which the cell, tissue,
polynucleotide, peptide, polypeptide, protein, dy or fragment(s) thereof, which are
normally associated in nature. For example, an isolated cell is a cell that is separated
from tissue or cells of ilar phenotype or genotype. An isolated polynucleotide is
separated from the 3' and 5' contiguous nucleotides with which it is normally associated
in its native or natural environment, e.g., on the chromosome. As is nt to those of
skill in the art, a non-naturally occurring polynucleotide, peptide, polypeptide, protein,
antibody or fragment(s) thereof, does not require "isolation" to distinguish it from its
naturally occurring rpart. The term "isolated" is also used herein to refer to cells or
tissues that are isolated from other cells or tissues and is meant to encompass both
cultured and ered cells or s.
Hepatitis C virus or "HCV" is a small (55-65 nm in size), enveloped, positive-
sense single-stranded RNA virus of the family Flaviviridae. Hepatitis C virus is the cause
of hepatitis C in humans. The hepatitis C virus particle consists of a core of genetic
al (RNA), surrounded by an icosahedral protective shell of protein, and further
encased in a lipid (fatty) envelope of cellular origin. Two viral envelope glycoproteins,
El and E2, are ed in the lipid envelope.
Hepatitis C virus has a ve sense single-stranded RNA genome. The genome
consists of a single open reading frame that is 9600 nucleotide bases long. This single
open reading frame is translated to produce a single protein product, which is then r
processed to produce smaller active proteins.
At the 5' and 3' ends of the RNA are the UTR, that are not translated into
proteins but are important to translation and replication of the viral RNA. The 5' UTR has
a ribosome binding site (IRES - Internal ribosome entry site) that starts the translation of a
very long protein containing about 3,000 amino acids. This large pre-protein is later cut
by cellular and viral proteases into the 10 smaller proteins that allow viral replication
within the host cell, or le into the mature viral particles.
Structural ns made by the hepatitis C virus include Core protein, El and
E2; nonstructural proteins include NS2, NS3, NS4, NS4A, NS4B, NS5, NS5A, and
NS5B.
Based on genetic differences between HCV es, the hepatitis C virus species
is classified into six genotypes (1-6) with several subtypes within each genotype
(represented by letters). Subtypes are further broken down into quasispecies based on
their genetic diversity. The preponderance and distribution of HCV genotypes varies
ly. For example, in North America, genotype l a predominates followed by lb, 2a,
2b, and 3a. In Europe, genotype lb is predominant followed by 2a, 2b, 2c, and 3a.
Genotypes 4 and 5 are found almost exclusively in Africa. pe is clinically
ant in determining ial response to interferon-based therapy and the required
duration of such therapy. Genotypes 1 and 4 are less responsive to interferon-based
treatment than are the other genotypes (2, 3, 5 and 6). Duration of standard interferonbased
therapy for genotypes 1 and 4 is 48 weeks, s treatment for genotypes 2 and 3
is ted in 24 weeks.
Sequences from different HCV genotypes can vary as much as 33% over the
whole viral genome and the sequence variability is distributed y throughout the
viral genome, apart from the highly conserved 5' UTR and core regions and the
hypervariable envelope (E) region.
HCV genotypes can be identified with various methods known in the art. PCR-
based genotyping with genotype-specific primers was first introduced in 1992, in
particular with primers targeting the core region. Commercial kits (e.g. , InnoLipa® by
Innogenetics (Zwijindre, Belgium)) are also available. Direct sequencing, in the vein, can
be used for more reliable and ive genotyping.
Serologic genotyping uses genotype-specific antibodies and identifies genotypes
indirectly. Two commercially available serologic genotyping assays have been
uced, including a RIBA SIA assay from Chiron Corp. and the Murex HCV
serotyping enzyme immune assay from Nurex Diagnostics Ltd.
Sequences of genotype 3 HCV have been identified. For ce, GenBank
accession # GU8 14264 provides the sequence of a subgenomic genotype 3a on
based on the S52 infectious clone. Further discussion of the genotype 3 and their
sequences are clinical impacts can be found at Zein Clin. Microbiol. Rev. 13(2):223-35
(2000).
The term "replicon" refers to a DNA molecule or R A molecule, or a region of
DNA or RNA, that ates from a single origin of replication. For most prokaryotic
somes, the replicon is the entire chromosome. In some aspects, a replicon refers
to a DNA or RNA construct that ates in a cell in vitro. In one aspect, a on can
replicate to produce at least about 10, or alternatively, at least about 100, 500, 1000, 2000,
5000, 10,000, 1 x 105, 1 x 106, 1 x 107, 1 x 108 or 1 x 109 copies of the replicon in a cell in
vitro. Alternatively, a replicon's replication efficiency can be measured by producing
certain amount of viral RNA in total RNA that includes cellular RNA. In one aspect, a
replicon can produce at least about 1000, 1 x 104, 1 x 105, 1 x 106, 1 x 10 , 1 x 108, 1 x
109, 1 x 10 10 , 1 x 10 11, or 1 x 10 12 copies of the replicon per microgram of total RNA or
cellular RNA.
A "subgenomic" HCV sequence refers to a HCV sequence that does not include
all sequences of a wild-type HCV. In one aspect, a subgenomic HCV or a subgenomic
HCV replicon does not include the El, E2 or C regions. In another , a subgenomic
HCV or a omic HCV replicon includes all or part of the 5' UTR, NS3, NS4A,
NS4B, NS5A, NS5B and 3' UTR sequences. In contrast, a "full-length" or "full genome"
HCV or HCV replicon includes El, E2 and C s. In some aspects, both a
subgenomic and a full-length HCV replicon can include one or more of a reporter gene
{e.g., luciferase), a marker gene {e.g., Neo), and an IRES {e.g., EMCV IRES) sequence.
A virus particle (or virion) consists of the genetic material made from either
DNA or RNA of a virus and a n coat that protects the genetic material. In one
, an envelope of lipids surrounds the protein coat when they are outside a cell.
The term "adaptive mutation" of a HCV replicon of a certain genotype refers to
a mutation, as ed to a wild-type HCV sequence of the genotype, that enables the
wild-type replicon to replicate in a cell, in particular in a eukaryotic cell such as a
mammalian cell and in vitro, or enhances a HCV replicon's y to replicate. It is
contemplated that an adaptive mutation can favorably influence assembly of the replicase
complex with host cell-specific protein, or alternatively promote interactions of the
protein that includes the ve mutation {e.g., NS3, NS4A, NS4B, NS5A etc) with
cellular proteins involved in host cell antiviral defenses.
1001321151
A “reporter gene” refers to a gene that can be attached to a regulatory sequence of
another gene of interest in cell culture, animals or plants, to facilitate identification of this other
gene. Reporter genes are often used as an indication of whether a certain gene has been taken up
by or expressed in the cell or organism population. Non-limiting examples of reporter gene
include the luciferase gene and the green fluorescent protein gene.
A “marker gene” or table marker” refers to a gene that protects the organism from
a ive agent that would normally kill it or prevent its growth. One non—limiting example is
the neomycin phosphotransferase gene (Neo), which upon expression s resistance to G418,
an aminoglycoside antibiotic similar in structure to gentamicin Bl.
HCVgenotype 3 replicon ucts
The present disclosure relates, in general, to the unexpected ery that clonal bell
lines stably replicating genotype 3 replicons can be obtained by transcribing and oporating
subgenomic genotype 3 cDNAs into HCV permissive cell lines. From the clonal cells, adaptive
mutations are then identified. One such adaptive mutation is N6078 at N83. r adaptive
mutation is P89L. The 822041 (82321 within NSSA) mutation is also applicable in this pe.
The effect of any one or more of these mutations can be further enhanced by one or more of
Q41R (N83), A166T (N83), A379T (N83 helicase domain), 8534G (N83 helicase ),
K583E (N83 se domain), 81C (N84A) or those provided in Tables 7-9.
Identification of these mutations suggests that these mutations contribute to the HCV’s
lity to ate in cells in vitro, a phenomenon not observed with wild—type HCV
genotype 3 RNA. Such contribution has been confirmed by engineering the mutations, by site-
directed mutagenesis, into pe 3 RNA and introducing them into the cell lines. Genotype 3
HCV RNA, with such mutations, successfully replicated in the cell lines. Therefore, the
Applicant has demonstrated that the Applicant has prepared HCV genotype 3 replicons capable
of replication in vitro and has identified adaptive mutations leading to such capabilities.
Accordingly, in one embodiment, the present disclosure provides a genotype 3 hepatitis
C viral (HCV) RNA that is capable of replication in a host cell. In one aspect, the replication is
in vitro. In one aspect, the replication is productive replication. In another aspect, the cell is a
eukaryotic cell such as a mammalian cell or a human cell. In yet another aspect, the cell is a
hepatoma cell. In some aspects, the RNA can ate to produce at least 10 copies of the RNA
1151
in a cell. In r aspect, the number of copies is at least about 100, 500, 1000, 2000, 5000,
,000,1x105,1X106,1X107,1x108 or 1 x 109.
The HCV RNA can be a subgenomic HCV sequence. It is specifically contemplated
that a full—length HCV replicon containing any or more of such adaptive mutations is also
capable to replicate. Still further, an entire HCV virus of the corresponding genotype containing
the adaptive mutation(s) would be ious and capable to replicate. In any such case, RNA can
include one or more of 5’NTR, an internal ribosome entry site (IRES), ces encoding NS3,
NS4A, NS4B, NSSA and NSSB, and a 3 ‘NTR. In one aspect, the RNA includes, from 5’ to 3’
‘ non-translated region (5 ‘NTR)
on the positive—sense nucleic acid, a functional HCV 5
comprising an e 5 ‘—terminal conserved ce; an HCV polyprotein coding region; and
a functional HCV 3’ non-translated region (3’NTR) comprising an extreme 3 ‘-terminal
conserved ce.
In any of the above embodiments, the HCV RNA can include an adaptive mutation that
enables the RNA to replicate in the cell. Such adaptive mutations can include an isoleucine at
location 2204 (residue 232) in NS5A, and/or a serine at residue 607 for N83. Another adaptive
mutation is P89L. The effect of any one or more of these ons can be further enhanced by
one or more of Q41R (N83), A166T (N83), A379T (NS3 helicase domain), SS34G (NS3
helicase domain), K583E (NS3 se domain), SIC (N84A) or those provided in Tables 7-9.
In one embodiment, provided are replicons listed in Table 3. It is specifically
contemplated that the HCV RNA can be a RNA sequence that has at least about 75%, or about
80%, 85%, 90%, 95%, 98%, 99%, or about 99.5% sequence identity to any of the disclosed
sequences, so long as it retains the corresponding adaptive mutation(s) and/or activities.
In another embodiment, provided is a genotype 3 HCV RNA construct comprising a 5
‘NTR, an internal ribosome entry site (IRES), sequences encoding NS3, NS4A, NS4B, NSSA
and NSSB, and a 3’NTR, wherein the construct is capable to replicate in a otic cell. In one
aspect, the uct comprises an adaptive on in NS3, NS4A, NS4B, NSSA or NSSB. The
mutation, in one aspect, comprises an isoleucine at location 2204 (residue 232) in NSSA, and in
another aspect, comprises, in N83, a serine at residue 607 and/or a leucine at residue 89. In some
aspects, the genotype 3 is genotype 3a.
100132l 151
In any of the above embodiments, the HCV RNA can further comprise a marker gene
for ion. A non-limiting example of such marker gene is a neomycin phosphotransferase
gene. Other examples are well known in the art.
In any of the above embodiments, the HCV RNA can further comprise a reporter gene.
A non—limiting example of such marker gene is a luciferase gene. Other examples are well
known in the art.
The RNA construct of any of the above embodiment can further se sequences
encoding one or more of C, E1 or E2. In one aspect, the RNA construct is a full—length HCV
replicon.
[0074] The disclosure also provides a single or double-stranded DNA that can be transcribed to
a RNA uct of any of the above embodiment, a viral particle comprising a RNA construct
of any of the above embodiment, or an isolated cell comprising a RNA construct of any of the
above embodiment.
In one aspect of any such embodiments, the genotype 3 is genotype 3a. In yet another
aspect, ed is a polynucleotide encoding the protein of any of such embodiments. The
polynucleotide can be RNA or DNA. In another , provided is an RNA or DNA construct
comprising the polynucleotide. In yet another aspect, provided is a cell comprising the
polynucleotide. Still in one aspect, provided is an antibody that specifically recognizes a protein
of any of the above embodiments.
HCV Genotype 3 Replicons and Cells Containing the Replicons
Another embodiment of the present disclosure provides an isolated cell comprising a
hepatitis C viral (HCV) RNA that is genotype 3, wherein the HCV RNA replicates in the cell. In
one , there is an absence, in the cell, of a DNA uct encoding the RNA and thus
copies of the HCV RNA are not transcribed from a DNA, such as cDNA, construct.
[0077] In one aspect, the cell comprises at least 10 copies of the RNA. In another , the
cell comprises at least 100, 500, 1000, 2000, 5000, 10,000, 1 x 105, 1 x 106, 1 x 107, 1 x108 or 1
x 109 copies of the RNA.
1001321151
The HCV RNA can be subgenomic HCV ce or a ength HCV sequence. In
either case, RNA can include one or more of 5’NTR, an internal ribosome entry site (IRES),
sequences encoding NS3, NS4A, NS4B, NSSA and NSSB, and a 3 ’NTR.
In any of the above embodiments, the HCV RNA can include an adaptive mutation that
enables the RNA to replicate in the cell. Such adaptive mutations can include an isoleucine at
on 2204 (residue 232) at NSSA.
In one embodiment, provided are replicons listed in Table 3. It is contemplated are that
the HCV RNA can be a RNA sequence that has at least about 75%, or about 80%, 85%, 90%,
95%, 98%, 99%, or about 99.5% ce identity to any of the disclosed sequences, so long as
it retains the corresponding adaptive mutation(s).
In one aspect, the cell is a eukaryotic cell such as a ian cell and in particular a
human cell. In another , the cell is hepatoma cell, such as but not limited to a Huh7 cell
(e. g. 51C and 1C). In some aspects, the cell is placed at an in vitro or ex vivo
, Huh7—Lunet,
condition.
Methods ofPreparing Genotype 3 Replicons
After HCV genotype 3 replicons are identified, as shown in Example 1, introduction of
the relevant adaptive mutation into a corresponding genotype HCV RNA can result in the RNA’s
capability to replicate, in particular in a ian cell in vitro. Accordingly, the present
disclosure provides a method of improving the capability of a genotype 3 HCV viral RNA to
replicate in a eukaryotic cell, comprising substituting residue 607 ofN83 with a serine or e
89 ofN83 with a leucine. In one aspect, a 822041 (residue 232) mutation or any secondary
mutation provided herein can further be introduced into the RNA.
Methods of Screening HCV Inhibitors Targeting Genotype 3
Numerous known and n HCV inhibitors have been tested for their
efficiency in inhibiting the genotype 3 HCV, in comparison with genotype lb (Example
1). Some showed higher efficacy for genotype 3, and some were not as efficacious. The
usefulness of the new identified genotype 3 replicons, ore, is adequately
demonstrated.
Thus, the present disclosure also provides, in one embodiment, a method of
identifying an agent that inhibits the replication or activity of a genotype 3 HCV,
comprising contacting a cell of any embodiment of the present sure with a ate
agent, wherein a decrease of replication or a decrease of activity of a protein d by
the RNA indicates that the agent inhibits the ation or activity of the HCV. In some
aspects, the protein is a protease, such as any or more of NS3, NS4A, NS4B, NS5A or
NS5B. Replication of the RNA, in one aspect, can be measured by a reporter gene on the
RNA, such as the luciferase gene.
Provided in another embodiment is a method of fying an agent that the
activity of a genotype 3 HCV, sing contacting the lysate of a cell of any
ment of the present disclosure with a candidate agent, wherein a decrease of the
activity of a protein encoded by the RNA indicates that the agent inhibits the activity of
the HCV. In some aspects, the protein is a protease, such as any or more of NS3, NS4A,
NS4B, NS5A or NS5B. In one aspect, the method further comprises measuring the
replication of the RNA or the activity of the protein encoded by the RNA.
A HCV inhibitor (or "candidate agent") can be a small molecule drug that is an
organic compound, a peptide or a protein such as antibodies, or nucleic acid-based such as
siRNA. In May 201 1, the Food and Drug Administration approved 2 drugs for Hepatitis
C, boceprevir and evir. Both drugs block an enzyme that helps the virus reproduce.
Boceprevir is a protease inhibitor that binds to the HCV NS3 active site on hepatitis C
genotype 1. Telaprevir inhibits the hepatitis C virus NS3.4A serine protease.
More conventional HCV treatment includes a combination of pegylated
eron-alpha-2a or pegylated eron-alpha-2b (brand names Pegasys or PEGIntron
) and the antiviral drug ribavirin. Pegylated interferon-alpha-2a plus rin may
increase sustained virological response among patients with chronic hepatitis C as
compared to pegylated interferon-alpha-2b plus ribavirin according to a systematic review
of randomized controlled .
All of these HCV inhibitors, as well as any other candidate , can be tested
with the disclosed methods for their efficacy in inhibiting HCV genotype 3 . The cells are
then incubated at a suitable ature for a period time to allow the replicons to
replicate in the cells. The replicons can include a reporter gene such as luciferase and in
such a case, at the end of the incubation , the cells are assayed for luciferase activity
as markers for replicon levels. rase expression can be quantified using a
commercial luciferase assay.
ately, cy of the HCV inhibitor can be measured by the expression or
activity of the proteins encoded by the replicons. One example of such proteins is the
NS3 protease, and ion of the protein expression or activity can be carried out with
methods known in the art, e.g., Cheng et a , Antimicrob Agents Chemother 55:2197-205
(2011).
Luciferase or NS3 protease ty level is then converted into percentages
relative to the levels in the controls which can be untreated or d with an agent
having known ty in inhibiting the HCV. A decrease in HCV replication or decrease
in NS3 activity, as compared to an untreated control, indicates that the candidate agent is
capable of inhibiting the corresponding genotype of the HCV. Likewise, a larger
decrease in HCV replication or larger decrease in NS3 activity, as compared to a control
agent, indicates that the candidate is more efficacious than the control agent.
EXAMPLES
The present disclosure is further defined by reference to the ing examples.
It will be apparent to those skilled in the art that many modifications, both to threads and
methods, may be practiced without departing from the scope of the current disclosure.
Abbreviations
Unless otherwise stated all temperatures are in degrees Celsius (°C). Also, in
these examples and elsewhere, abbreviations have the following meanings:
e 1: Generation of Robust Genotype 3 Hepatitis C Virus Subgenomic
Replicons
This example shows that adaptive mutations were identified from genotype 3
HCV viral replicons capable of replication in Huh7 cells and that HCV replicons with
these ve mutations are useful tools for antiviral drug screening.
Materials and Methods
Cell Culture
Three HCV permissive cell lines were used during these studies: Huh7-Lunet,
51C, and 1C. Huh7-lunet was obtained from ReBLikon GmbH (Mainz, Germany)
(Friebe et a , J Virol 79:380-92 (2005)). The derivation of 51C cells, and stable genotype
l a H77 and genotype lb Con-1 Rluc-Neo on cells were previously described (see
Robinson et a , crob Agents Chemother 54:3099-106 (2010)). 1C cells were
derived by curing a 5-resistant genotype l a replicon clone derived from 51C cells
(id.). GS-5885 is an NS5A inhibitor, available from Gilead Sciences, Inc., Foster City,
CA. This clonal line showed the highest permissivity to GTla and lb replicons out of
screened 50 clones and was 5-10 folds more permissive than Huh7-Lunet and 51C cells
overall. All cell lines were propagated in Dulbecco's modified Eagle's medium (DMEM)
with GlutaMAX-I (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS; HyClone, Logan, UT), 1 unit/ml penicillin (Invitrogen), 1 mg/ml streptomycin
(Invitrogen), and 0.1 mM non-essential amino acids (Invitrogen); this media ation
is referred to as complete DMEM. Replicon cell lines were selected and maintained in
complete DMEM ning 0.5 mg/ml G418 (Geneticin; Invitrogen).
Construction ofPlasmids Encoding Genotype 3a HCV Subgenomic Replicons
A plasmid (pGT3aS52SG) encoding a subgenomic genotype 3a replicon based
on the S52 ious clone (GenBank accession # GU8 14264) was prepared by DNA
synthesis cript, Piscataway, NJ) and g. The synthesized replicon
incorporated following elements from 5' to 3' (: (1) the S52 5'UTR, ing
to the first 48 nucleotides of core, (2) a linker with the tide sequence, 5'-
GGCGCGCCA -3 (SEQ ID NO: 1) which introduces the Ascl restriction site
(underlined), (3) the neomycin phosphotransferase II (neo) gene, (4) a linker with
nucleotide ce, 5 -GGCCGGCCGCGGCCGCAA -3 (SEQ ID NO: 2) which
introduces Fsel and Not I restriction sites (underlined), (5) the encephalomyocarditis virus
(EMCV) IRES, (6) a linker with nucleotide sequence 5 -ACGCGTATG -3 (SEQ ID NO:
3) which introduces the Mlul restriction site (underlined) and an ATG start codon for
HCV polyprotein expression, (7) the NS3 - NS5B polyprotein region of S52 including an
NS5A adaptive mutation (S2204I) and (8) the 3'UTR of S52. The synthetic DNA
fragment ng the S52 replicon was inserted into PUC19 between EcoRI and Xbal
restriction sites.
Plasmid p/zRlucNeoSG2a was derived from the plasmid pLucNeo2a (Cheng et
al., Antimicrob Agents Chemother 55:2197-205 (201 1)). The hRenilla rase-
Neomycin fusion gene (hRluc-Neo) was PCR amplified from pF9 CMV hRluc-neo
Flexi(R) (Promega, Madison, WI) by PCR using Accuprime Super Mix I rogen) and
a primer set of Afel hRLuc Fwd and NotI Neo Rev. These two primers had the following
sequence and introduced restriction sites for subsequent cloning: Afel hRLuc: 5'
ATAGCGCTATGGCTTCCAAGGTGTACGA 3' (SEQ ID NO: 4, Afel site underlined),
NotI Neo Rev: 5' AATGCGGCCGCTCAGAAGAACTCGTCA 3' (SEQ ID NO: 5, NotI
site underlined). The hRluc-Neo amplification product was subcloned into pCR2.1-TOPO
(Invitrogen). The resulting plasmid was digested with Afel and NotI, and the excised
fragment (hRluc-Neo) was d with T4 DNA ligase (Promega) into pLucNeo2a
digested with the same enzymes. The resulting , phRlucNeoSG2a, was ced
to ensure correct orientation and sequence of the hRluc-Neo fusion gene.
The subsequent PCR fragment was cut with Ascl and Mlul and gel purified
using a commercial kit (Qiagen). The vector and insert pieces were ligated using
LigaFast Rapid DNA on System per manufacturer's protocol (Promega).
Construction of Mutant Replicons
Adaptive ons were introduced into the replicon by site directed
mutagenesis using a ange Lightening kit (Stratagene, La Jolla, CA). All mutations
were confirmed by DNA sequencing by TACGen (Hayward, CA).
RNA Transcription
Plasmids encoding genotype 3a subgenomic HCV replicons were linearized with
Xbal and purified using a PCR purification kit (Qiagen). RNA was synthesized and
purified with T7 MEGAScript n, Austin, TX) and RNeasy kits, respectively,
according to the manufacturer's instructions. RNA concentrations were measured using
optical density at 260 nm and confirmed by 0.8% agarose gel electrophoresis rogen).
RNA Transfection and Isolation of Stable Replicon Cell Lines
Ten micrograms of in v tro-transcribed RNA were transfected into Huh7-Lunet,
51C, or 1C cells by electroporation as usly described (Robinson et a , Antimicrob
Agents Chemother 54:3099-106 (2010)). Briefly, cells were collected by trypsinization
and centrifugation, then washed twice with ice-cold phosphate buffered saline (PBS) and
resuspended in Opti-MEM medium (Invitrogen) at a concentration of 10 cells/ml.
Replicon RNA was added to 400 mΐ of cell suspension in a Gene Pulser (BioRad,
Hercules, CA) cuvette m gap). Cells were electroporated at 270 V and 960 mE,
incubated at room temperature for 10 minutes, resuspended in 30 ml complete DMEM
and then plated into 100-mm-diameter dishes. Forty-eight hours after plating, medium
was replaced with complete DMEM supplemented with 0.5 mg/ml G418 which was
refreshed twice per week. Cell clones were isolated after approximately three weeks of
G418 ion, expanded, and eserved at early passages.
Replicon Colony Formation Assays
To determine the efficiency of G4 18-resistant colony formation, cells were
electroporated with indicated amounts of replicon RNA or cellular RNA t, and
plated at le densities ranging from 2 x 105 to 2 x 106 cells/ 100mm dish. Forty-eight
hours after plating, medium was replaced with te DMEM supplemented with 0.5
mg/ml G418 which was refreshed twice per week. Three weeks later, colony plates were
used for cell expansion or G4 18-resistant foci were fixed with 4% formaldehyde and
stained with 0.05% crystal violet in H20 .
Extraction, amplification, and genotypic analysis of HCV RNA
HCV RNA ion, RT-PCR, and sequencing were med by TACGen
(Hayward, CA). HCV replicon cellular RNA was extracted and purified using an RNeasy
kit (Qiagen) according to the cturer's protocol. RT-PCR was performed using the
Superscript III first-strand synthesis system (Invitrogen). PCR products were sequenced
by TACGen (Hayward, CA).
Detection ofNSSA n by indirect immunofluorescence
Replicon cells were plated in 96-well plates at a density of 1 x 104 cells per well.
After cultured for 24 hours, cells were then stained for NS5A protein as described
previously (Cheng et a , Antimicrob Agents her 55:2197-205 (201 1)). Briefly,
cells were fixed in 4% paraformaldehyde for 20 minutes. Cells were then washed three
times with PBS, blocked with 3% bovine serum albumin, 0.5% TritonX-100, and 10%>
FBS and then stained with anti-NS5A antibody. Staining was performed using a 1:10,000
dilution of mouse monoclonal antibody 9E10 (Apath, Brooklyn, NY). After washing in
PBS three times, a secondary anti-mouse antibody conjugated to Alexa Fluor 555 was
used to detect anti-NS5A antibody labeled cells (Invitrogen). Nuclei were stained with 1
mg/ml Hoechst 33342 (Invitrogen). Cells were washed with PBS and imaged with a Zeiss
scence microscope (Zeiss, Thornwood, NY).
Replicon cell S S3 protease assayfor replicon RNA replication
pe 3a clonal replicons cells were seeded in 96-well plates at a
concentration of 1 x 104 cells per well. The cells were incubated for 24 hours, after which
culture media were removed. The replicon cells were then lysed with 90 mΐ o lx Promega
luciferase lysis buffer supplemented with 150 mM NaCl at room ature for 20 min
on a plate shaker. 10 mΐ of 1 mM europium-labeled NS3 substrate in the above lysis buffer
was added to each well. Protease activity data were ted and analyzed as previously
described (Cheng et a , Antimicrob Agents Chemother 55:2197-205 (201 1)).
Replicon Antiviral Assays
2,000 cells/well were seeded in 384-well plates in 90 mΐ of DMEM e
medium, excluding G418. Compounds were added to cells at a 1:225 dilution, ing a
final concentration of 0.44% in a total volume of 90.4 mΐ . Three-fold serial drug dilutions
with 10 concentrations were used, and starting concentrations were 4.4 mM or 0.44 mM
for all the tested compounds, except Compound A whose starting concentrations was 44.4
nM. Cell plates were incubated at 37°C for 3 days, after which culture medium was
removed and cells were assayed for luciferase ty as markers for replicon levels.
Luciferase expression was quantified using a cial luciferase assay (Promega).
Luciferase or NS3 protease activity levels were converted into percentages relative to the
levels in the untreated controls (defined as 100%), and data were fitted to the logistic dose
response on y _ a/[l_(x/b)c] using XLFit4 software (IDBS, Emeryville, CA) (y is
the amount of normalized luciferase signal, x is the drug concentration, a represents the
s amplitude, b is the x value at its transition center [EC 50], and c is a parameter
which defines its transition width).
Results
ve Mutations
Using the methods similar to those for genotype 4, Huh7-Lunet cell colonies
containing genotype 3 replicons were identified. Huh7-Lunet, 51C and 1C cells were
transfected with the GT3a replicon R A as described in the Materials and Methods. The
numbers of surviving colonies were counted for each selection. The data represent the
total number of colonies ed from at least 6 independent transfections in each cell
line. Huh7-Lunet was obtained from ReBLikon GmbH , Germany). The
derivation of 51C cells was previously described (Robinson et a , Antimicrob Agents
Chemother 54:3099-106 (2010). 1C cells were derived by curing a GSresistant
genotype l a replicon clone derived from 51C cells. Transfection of Huh7-Lunet yielded
two colonies that replicated the GT3a replicon and could subsequently be expanded into
cell lines. Transfection of the other two cell lines did not yield any viable colonies (Table
1001321151
Table 1. Selection of stable GT3a replicon clones in Huh7-Lunet cells.
Huiflmel! Eitw
Number (if CUIDfii'Efi
Total cellular R A from 50000 GT3a replicon cells (expanded from a colony established
in Huh7-Lunet cells described in Table 1) was extracted using a virus RNA QIAamp kit
(Qiagen) as ended by the manufacturer. Half of the total cellular RNA was then
electroporated into Huh7—Lunet cells and the other half into IC cells. Transfected cells were
ended in complete DMEM medium and plated at a density of 1 x 106 and 3 x 106 cells in
150 mm-diameter . Forty-eight hours after g, medium was replaced with complete
DMEM supplemented with 0.25 mg/ml G418 which was refreshed twice per week. Twenty five
days later, colonies were counted from all the dishes and the sum is presented in Table 2 for
each cell line. In vitro transcribed GT3a replicon RNA was transfected in parallel as a control.
The replicon RNA ted from the GT3a replicon cells y contained adaptations that
greatly enhanced its colony formation efficiency compared to the original al replicon.
Table 2. Selected GT3a replicon clones acquired ve genetic changes.
The selected GT3a replicon clone was expanded and subjected to pic analysis.
Total cellular RNA was extracted and purified using a RNeasy kit (Qiagen). RT-PCR was
performed using the Superscript III first-strand synthesis system (lnvitrogen). PCR products
were sequenced by TACGen (Hayward). The genotypic analysis identified the NS3 mutation
N607S as an adaptive mutation (Table 3).
Table 3. A NS3 Mutation N607S identified in genotype 3a replicon cell line.
Mtttzttinu N83] V
; mama-3
Different classes of HCV inhibitors that target N85 A, NSSB active site, N83
protease, NSSB non-active sites, NS4A and host factors, were evaluated for their antiviral
activities against stable genotype lb and genotype 3a Rluc-Neo replicon cells. Like in stable
genotype 1b replicon cells, EC50 values against genotype 3a replicon were
generated successfully for all the inhibitors in a high throughput 384-well format by
measuring NS3 protease activity.
The data ted in Table 4 and 3 indicate that Compound B remained
potent against genotype 3a replicon. However, Compound B lost 2.5-5 fold potency in
comparison with its activities against genotype l b replicon. In contrast, Compound A had
decreased activities against genotype 3a replicon > 20000-fold respectively. r,
Compound D and Compound E lost their activities to a level below 4.44 mM . Compound
C had decreased ties against genotype 3a replicon 58-fold than its genotype l b
activities.
These results demonstrate this novel genotype 3a on could serve as a
valuable tool for drug discovery and lead compound optimization against HCV genotype
Table 4 . ison of antiviral activities of HCV inhibitors against genotype l b and 3a
replicons
Compounds GTlb RLucNeo EC50 (nM) GT3a RlucNeo EC50 (nM)
Compound A 0.002 > 44.4
Compound B 117.3 281.1
Compound C 7.0 409.0
Compound D 0.47 > 4444.4
Compound E 0.55 > 4444.4
Here the Applicant reports the isolation of the first GT3a replicons that
efficiently replicate in vitro. It is demonstrated that robust replication es adaptive
mutations. By incorporating adaptive mutations into luciferase encoding ucts,
ant was able to generate GT3a replicon cell clones that will enable one to profile
antiviral compounds. These replicon cells should also serve as valuable tools for
molecular gy studies and the characterization of resistance mutations emerging in
HCV genotype 3 patients.
In summary, subgenomic replicon cDNAs based on the genotype 3a S52 strain
were sized, , transcribed and electroporated into HCV permissive cell lines.
Clonal cell lines stably replicating pe 3a replicons were selected with G418.
Adaptive mutations were identified by RT-PCR amplification and DNA sequencing and
engineered into the parental replicons by site-directed mutagenesis.
Numerous electroporations into multiple different permissive cell lines allowed
the identification of a few colonies that replicated either genotype 3 ons. ion
and cing of these replicons clones revealed adaptive ons in viral proteins.
One mutation identified so far was d in NS3 (N607S).
The establishment of robust genotype 3a replicon systems provides powerful
tools to facilitate drug discovery and development efforts. Use of these novel replicons in
conjunction with those derived from other genotypes will aid in the development of pan-
genotypic HCV ns.
Example 2. ing of New HCV Inhibitors for Genotype 3
Example 1 shows that agents known to be HCV tors for other genotypes,
such as genotype 1, can be tested with the genotype 3 replicons for their efficacy in
inhibiting pe 3 HCV. It is also contemplated that agents not yet known to be
inhibitory of HCV can be screened with these pe 3 replicons as well.
The candidate HCV inhibitor can be a small molecule drug, a peptide or a
protein such as antibodies, or nucleic acid-based such as siRNA. The candidate HCV
inhibitor is incubated with cells that contain a genotype 3 replicon, at a suitable
temperature for a period time to allow the replicons to replicate in the cells. The replicons
can include a reporter gene such as luciferase and in such a case, at the end of the
incubation period, the cells are assayed for rase activity as markers for replicon
levels. Luciferase expression can be quantified using a commercial rase assay.
Alternately, efficacy of the HCV inhibitor can be measured by the expression or activity
of the proteins encoded by the replicons. One example of such proteins is the NS3
protease, and detection of the protein expression or ty can be carried out with
methods known in the art, e.g., Cheng et al, Antimicrob Agents Chemother 55:2197-205
(2011).
Luciferase or NS3 protease activity level is then converted into percentages
relative to the levels in the controls which can be untreated or treated with an agent
having known activity in inhibiting the HCV. A decrease in HCV replication or decrease
in NS3 activity, as compared to an untreated control, indicates that the candidate agent is
capable of inhibiting the corresponding genotype of the HCV. Likewise, a larger
decrease in HCV replication or larger decrease in NS3 activity, as compared to a control
agent, tes that the candidate is more efficacious than the control agent.
Example 3. Generation of Genotype 3a HCV Subgenomic Replicons Containing a
P89L Mutation
This example describes the isolation of genotype 3a replicons that efficiently
replicate in vitro. This study demonstrates that robust replication was achieved based on
an adaptive mutation P89L in the NS3 protease domain, which could be further
augmented by mutations in NS3, NS4A, and NS5A. By incorporating P89L into
luciferase encoding constructs, this example generated stably replicating genotype 3a
replicon cell lines, and by combing with ed host cells cured of genotype 3 replicons,
efficient replication of genotype 3a HCV RNA was established in a transient-trans fected
cell culture. This system is fully capable of supporting potency profiling of ral
nds and selecting and phenotyping al resistance s emerging in HCV
genotype 3 ts. These replicons should also serve as a valuable system for molecular
virology studies of genotype 3 HCV, including a better tanding of its association
with a high incidence of liver steatosis.
MATERIALS AND METHODS
Cell culture. Huh7-Lunet cells were obtained from ReBLikon GmbH (Mainz,
Germany) (Friebe et al., J Virol 2005;79:380-92). 51C cells were derived by curing a
unet-based genotype l a replicon clone and were described in Robinson et al.,
Antimicrob Agents Chemother 2010;54:3099-106. 1C cells were derived by curing a GS-
5885-resistant genotype l a replicon clone d from 51C cells, and showed much
higher permissiveness to genotype l a replicon replication. All cell lines were propagated
in Dulbecco's modified Eagle's medium (DMEM) with GlutaMAX-I (Invitrogen,
Carlsbad, CA) mented with 10% fetal bovine serum (FBS; HyClone, Logan, UT), 1
unit/ml penicillin (Invitrogen), 1 mg/ml streptomycin (Invitrogen), and 0.1 mM non
essential amino acids (Invitrogen) (complete DMEM). Replicon cell lines were selected
and maintained in complete DMEM containing 0.25 to 0.5 mg/ml G418 icin;
Invitrogen).
Generation of cured cell lines. The cell lines l, GT3a-C2, and GT3a-
C3 are 1C clones stably replicating the genotype 3a pGT3aS52SG-Neo replicon. To cure
1001321151
these cell lines of HCV RNA, they were cultured in the presence of IFN (1000 IU/ml), the
NSSB nucleoside inhibitor 2’-CMeA (2 uM), the NSSA inhibitor EMS-790052 (500nM), and
the non-nucleoside NSSB inhibitor HCV—796 (1 uM). Cells were ed in medium
containing the four drugs twice a week for a total of eight passages. Cured cells were fully
sensitive to G418 (500 mg/ml, also known as Geneticin®, an aminoglycoside antibiotic) and
lacked detectable NSSA staining, ing the absence of the replicon. Cured cell lines were
expanded and cryopreserved at early e levels. Cured cells were designated 3a-Cl, 3a-C2,
and 3a—C3.
Construction of plasmids encoding pe 3a HCV subgenomic replicons. A
plasmid (pGT3aS52NeoSG) encoding a subgenomic genotype 3a replicon based on the S52
infectious clone (GenBank accession #GU814263, which encodes polyprotein sequences
provided in GenBank accession #ADF97231) was prepared by DNA synthesis (GeneScript,
Piscataway, NJ) and cloning. The synthesized on incorporated following elements from
’ to 3’ (: (1) the S52 5TJTR (339 nt), plus the first 48 nucleotides of core, (2) a linker
with the tide sequence 5 ‘-GGCGCGCCCA—3 ‘ (SEQ ID NO: 6), which introduces the
AscI restriction site (underlined), (3) the in phosphotransferase II (neo) gene, (4) a
linker with nucleotide sequence 5’-GGCCGGCCA-3’ (SEQ ID NO: 7), which introduces the
Fsel restriction site (underlined), (5) the encephalomyocarditis virus (EMCV) IRES, (6) a
linker with nucleotide sequence 5 GTATG-3 ‘ (SEQ ID NO: 3), which introduces the
Mlul restriction site lined) and an ATG start codon for HCV polyprotein expression, (7)
the NS3 — NS5B polyprotein region of S52 including an NSSA adaptive mutation (822101;
equivalent to S2204l in genotype 1, or S2321 within NSSA), and (8) the 3TJTR of S52 (235
nt). The synthetic DNA fragment encoding the SS2 replicon was inserted into pUC57 between
EcoRI and XbaI ction sites.
[0123] A second plasmid (pGT3aSS2RlucNeoSG) encoding a subgenomic replicon that
incorporated the humanized Renilla luciferase (thuc) reporter gene was generated as follows:
The pGT3aSS2NeoSG plasmid (described above) was cut using A501 and Mlul ction
enzymes (to remove the neo gene) and gel purified using a commercial kit (Qiagen, Valencia,
CA). A gene fragment encoding the thuc gene fused with the neo gene along with the EMCV
region from p/leucNeoSG2a plasmid (described below) were PCR amplified using
Accuprime super mix I (Invitrogen) with the following primers: 2aRlucNeoAscIFor: 5’-AAC
ACC ATC GGC GCG CCC ATG GCT TCC AAG GTG
TAC GAC -3' (SEQ ID NO: 8, AscI site is introduced by the primer and is underlined),
2aEMCVIRESMluIRev: 5'-TCGGGG CCA TAC GCG TAT CGT GTT TTT CAA AGG
-3' (SEQ ID NO: 9, Mlul site underlined). The subsequent PCR fragment was cut with
AscI and Mlul and gel purified using a commercial kit n). The vector and insert
pieces were ligated using the LigaFast Rapid DNA on System per the
manufacturer's protocol (Promega, Madison, WI). The resulting vector,
pGT3aS52RlucNeoSG, was sequenced to confirm the correct orientation and sequence of
the hRluc-Neo. The p/zRlucNeoSG2a plasmid was constructed by replacing the Luc-Neo
fragment in the plasmid pLucNeoSG2a with the hRluc-Neo gene ied from the
plasmid hRluc-Neo Flexi(R) (Promega) as previously described (Robinson et a ,
Antimicrob Agents Chemother 2010;54:3099-106 and Cheng et al, Antimicrob Agents
Chemother 2011;55 :2 5).
A third plasmid (Pi-GT3aS52RlucSG), encoding a bicistronic replicon with the
hRluc reporter gene ream of the poliovirus IRES (PI) and the genotype 3a (S52
strain) HCV nonstructural genes (NS3-NS5B) downstream of the EMCV IRES was used
for transient transfection s. The d was ted as follows: The
pGT3aS52RlucNeoSG plasmid (described above) was cut using AscI and Mlul restriction
enzymes (to remove the Rluc-Neo gene) and gel purified using a commercial kit
(Qiagen). A gene nt encoding the PI, hRluc gene and EMCV region was PCR
amplified from a genotype lb plasmid ( using Accuprime super mix I (Invitrogen) with
the following s: 3aPiRlucAscIFor: 5'-AAC ACC ATC GGC GCG CCA AAC CAA
GTT CAA TAG-3' (SEQ ID NO: 10, AscI site is introduced by the primer and is
underlined), IbEMCVIRESMluIRev: 5'-TCG GGG CCA TAC GCG TAT CGT GTT
TTT CAA AGG -3' (SEQ ID NO: 11, Mlul site underlined). The subsequent PCR
fragment was cut with AscI and Mlul and gel purified using a commercial kit (Qiagen).
The vector and insert pieces were ligated using LigaFast Rapid DNA Ligation System per
the manufacturer's protocol (Promega). The resulting vector, Pi-GT3aS52RlucSG, was
sequenced to confirm the correct orientation and sequence of the PI-hRluc region of the
gene.
Construction of mutant replicons. ve mutations were introduced into
the pGT3aS52RlucNeoSG or Pi-Rluc-GT3aS52 replicons by site-directed mutagenesis
using a ange ning kit (Stratagene, La Jolla, CA). All mutations were
confirmed by DNA sequencing by TACGen (Hayward, CA).
RNA transcription. ds encoding pe 3a subgenomic HCV
replicons were linearized with Xbal and purified using a PCR purification kit (Qiagen).
RNA was synthesized and purified with T7 MEGAScript (Ambion, Austin, TX) and
RNeasy kits (Qiagen), respectively, according to the manufacturer's instructions. RNA
concentrations were measured using optical density at 260 nm and confirmed by 0.8%
agarose gel electrophoresis (Invitrogen).
RNA transfection and isolation of stable replicon cell lines. Ten micrograms
of in v tro-transcribed RNA were transfected into Huh7-Lunet or 1C cells by
oporation as previously described (Robinson et a , Antimicrob Agents Chemother
2010;54:3099-106). Briefly, cells were collected by trypsinization and centrifugation,
then washed twice with ice-cold phosphate buffered saline (PBS) and resuspended in
EM medium (Invitrogen) at a concentration of 10 ml. Replicon RNA was
added to 400 mΐ of cell suspension in a Gene Pulser (BioRad, Hercules, CA) cuvette (0.4-
cm gap). Cells were electroporated at 270 V and 960 mE, incubated at room temperature
for 10 minutes, resuspended in 30 ml complete DMEM and then plated into two 100-mm-
diameter dishes. eight hours after g, medium was replaced with complete
DMEM supplemented with 0.25 mg/ml G418, which was refreshed twice per week. After
three weeks, cell clones were isolated, expanded with 0.5 mg/ml G418, and cryopreserved
at early passages.
Replicon colony formation assays. To determine the efficiency of G418-
resistant colony ion, cells were electroporated with the indicated s of
on RNA or extracted cellular RNA, and plated at multiple densities ranging from 2
105 to 2 106 cells/100-mm dish. Forty-eight hours after plating, media were replaced
with complete DMEM supplemented with 0.5 mg/ml G418, which was refreshed twice
per week. Three weeks later, colony plates were used for cell expansion or G418-
resistant foci were fixed with 4% formaldehyde and stained with 0.05% l violet.
Extraction, amplification, and genotypic analysis of HCV RNA. HCV RNA
isolation, RT-PCR, and population sequencing were performed by TACGen. Briefly,
HCV replicon cellular RNA were extracted and purified using an RNeasy kit (Qiagen)
according to the manufacturer's protocol. RT-PCR was performed using the Superscript
III first-strand synthesis system (Invitrogen), and PCR products were uently
sequenced by TACGen.
Detection of NS5A protein by ct immunofluorescence. Replicon cells
were plated in 96-well plates at a density of 1 104 cells per well. After incubation for 24
hours, cells were then stained for NS5A protein as described previously (Cheng et a ,
Antimicrob Agents Chemother 201 1;55:2 197-205). Briefly, cells were fixed in 4%
paraformaldehyde for 20 minutes. Cells were then washed three times with PBS, blocked
with 3% bovine serum albumin, 0.5% Triton X-100, and 10% FBS and stained with anti-
NS5A antibody. Staining was performed using a 1:10,000 dilution of mouse monoclonal
antibody 9E10 (Apath, Brooklyn, NY). After washing in PBS three times, a secondary
ouse antibody conjugated to Alexa Fluor 555 was used to detect anti-NS5A
antibody labeled cells (Invitrogen). Nuclei were stained with 1 mg/ml Hoechst 33342
(Invitrogen). Cells were washed with PBS and imaged with a Zeiss fluorescence
microscope , Thornwood, NY).
Detection of NS5A protein by Western blot. The stable GT3a replicon clones
and pooled cell line, as well as GTlb replicon cells, were pelleted and lysed in SDS
loading buffer. Lysates were then subjected to SDS-PAGE and Western blot analysis.
The blot was d with primary anti-NS5A antibody (Apath; 1:3000 dilution) and
secondary anti-mouse antibody (IRDye 800CW Goat anti-Mouse IgG (H + L) from LI-
COR [Lincoln, Nebraska], 00 dilution). The blot was also co-stained with anti-BiP
antibody , 1:1000 dilution) and secondary anti-rabbit dy (IRDye 800CW
Goat abbit IgG (H + L) from LI-COR, 1:10,000 dilution) as a loading control.
Staining was analyzed by Odyssey Imaging (LI-COR).
Replicon antiviral assays. Replicon RNA were electroporated into 1C cells as
described above. After transfection, cells were quickly transferred into 100 mL of pre-
warmed culture medium, and 90 mΐ was seeded in 384-well plates at a density of 2,000
cells/well. Cells were treated with three-fold serial drug dilutions at 10 different
concentrations. Cell plates were incubated at 37°C for 3 days, after which culture
medium was d and cells were d for luciferase activity as markers for
replicon levels. rase expression was fied using a commercial luciferase assay
(Promega). Luciferase levels were converted into tages relative to the levels in the
ted controls (defined as 100%), and data were fitted to the logistic dose-response
equation y = a/[l+(x/b) ] using XLFit4 software (IDBS, Emeryville, CA).
Antiviral compounds. VX-950 (telaprevir), boceprevir, and 2-C-methyl
adenosine (2-CMeA) were purchased from Acme Bioscience (Belmont, CA).
Cyclosporine A (CsA) was purchased from Sigma-Aldrich (St. Louis, MO). The Wyeth
HCV NS5B site IV inhibitor HCV-796 was synthesized by Curragh Chemistries
(Cleveland, OH). Gilead compounds GS-5885, 0, 1, GS-9669, and GS-
7977, Pfizer NS5B thumb site II inhibitor filibuvir, Merck NS5B thumb site I inhibitor
MK-3281 and protease tor MK-5172, and the Bristol-Myers Squibb NS5A inhibitor
(BMS-790052) were synthesized by Gilead Sciences.
RESULTS
Construction of a subgenomic genotype 3a replicon and colony formation in
permissive Huh-7 clones. A subgenomic genotype 3a replicon was constructed as
previously described by Lohmann et a , Science 85:1 10-3 and based on the
consensus sequence (GenBank accession #GU814263) of the genotype 3a S52 strain
(. The S52 strain was selected due to its robust infection in chimpanzees. To
enhance the basal level of ation, an NS5A mutation S2210I (equivalent to S2204I in
genotype la) was incorporated.
In v tro-transcribed replicon R A was electroporated into Huh7-Lunet, 51C, or
1C cells. In Huh7-Lunet cells, no stable replicon colony emerged after six attempts of
transfection each with 10 mg of RNA (Table 5). r results were also seen in 51C
cells that were ed by curing a genotype l a replicon clone derived from Huh7-Lunet
cells, indicating a very low colony formation efficiency of genotype 3a replicons in these
two highly pe 1 replicon-permissive cell lines. In contrast, in 1C cells that were
selected by curing a GSresistant genotype l a replicon clone derived from 51C
cells, three stable colonies could be selected from five transfections (Table 5). This result
suggests that although genotype 3 HCV has a very low replication efficiency in cell
e, the 1C cells that showed higher permissiveness to genotype l a replicon
replication than 51C and unet cells provide better support to genotype 3 HCV
replication and permit establishment of stable G41 8-resistant colonies.
Table 5. 1C cells are more permissive than Huh7-Lunet cells to GT3a replicon
replication
Huh7-Lunet, 51C and 1C cells were transfected with genotype 3a replicon RNA. The number of
surviving colonies was d for each selection transfected with 10 mg RNA.
Characterization of stable genotype 3a replicon clones. To confirm that the
ed colonies harbored replicating genotype 3a replicons, an immunohistochemical
and Western analysis were med. The stable genotype 3a replicon cell lines were
lysed in SDS loading buffer and analyzed by Western blot. An anti-NS5A antibody
readily detected NS5A protein in all three genotype 3a replicon cell lines at levels only
ly lower than those in the genotype l b replicon cell line (; data not shown
for genotype 3a #3 clone that was ed and analyzed later). Similar to genotype lb,
only the p56 form of NS5A protein was detected in these replicon clones, likely due to the
ce of a S2210I (equivalent to S2204I in genotype 1) mutation in the NS5A protein.
Furthermore, an immunohistochemical analysis of the genotype 3a replicon cell line using
S5A antibody confirmed the expected sion pattern for NS5A, particularly in
the perinuclear region. In contrast, sfected parental 1C cells did not show
detectable NS5A protein ().
The very low colony formation efficiency of genotype 3a on RNA, even in
1C cells, suggests that ve mutations may have been acquired in the colonies that did
emerge. To investigate whether there were adaptive changes in viral genomes in
genotype 3a replicon colonies, total cellular RNA was extracted from the genotype 3a
replicon clone # 1 and re-electroporated into naive Huh7-Lunet cells. Transfected cells
were then cultured in the presence of G418, and colony formation was monitored. In
vzYro-transcribed genotype 3a replicon RNA was ected in parallel for comparison.
Consistent with the data in Table 5, 16 mg of parental replicon RNA did not yield a viable
colony in Lunet cells. In contrast, trans fection of 1 mg total cellular RNA extracted from
the genotype 3 cell line, only a small fraction of which was HCV RNA, yielded more than
> 200 colonies (. Similar results were also seen with replicon clones #2 and #3
(data not shown). These results confirm that the selected genotype 3a replicon clones
ed ve mutation(s) and became capable of replicating efficiently in vitro.
Genotypic analyses of genotype 3a replicon clones. To identify adaptive
mutations, genotype 3a replicon clones were subjected to genotypic analyses. Total
cellular RNA was extracted, and HCV replicon RNA was subsequently amplified by RT-
PCR. PCR products that cover the entire NS3-NS5B region were sequenced by
population sequencing. Amino acid changes in each clone are summarized in Table 2 .
All clones had an amino acid substitution of leucine with proline at residual position 89
(P89L) within the viral NS3 protease domain. Clone #3 had an additional mutation,
Q41R, that was also located in the NS3 protease domain. A number of individual clones
or pools were also selected from the total cellular RNA retransfection study shown in
and were analyzed for genotypic changes. Although a number of mutations were
fied in individual clones and buted throughout viral NS3, NS4A, NS4B, or
NS5A proteins, they all ed in conjunction with P89L (Table 7). These results
te that P89L serves as a primary adaptive mutation for HCV genotype 3 RNA
replication in cell e.
Table 6. ons identified in GT3a replicon cells lines
Table 7. Mutations identified in genotype 3a-neo replicon cells lines
Generation of cell lines stably replicating luciferase-encoding genotype 3a
replicons. To investigate whether emerging mutations enhanced replicon replication, the
mutation P89L in NS3 was introduced into the parental genotype 3a replicon sequence
(. To facilitate measurement of replication in cell culture, the Neo gene in the
parental pe 3a replicon construct () was replaced with a Renilla luciferase
(Rluc)-neo fusion reporter as shown in . Huh7-Lunet or 1C cells were
transfected with Rluc-neo on RNA ng the adaptive mutation P89L in NS3
and were cultured in the presence G418. In parallel, parental genotype 3a neo and Rluc-
neo constructs were also transfected and selected in unet or 1C cells. Consistent
with the results in Table 1, the Neo on yielded an average of one colony per
selection in 1C cells and no colony in unet cells (. Interestingly, the Rluc-
neo replicon without adaptive mutations failed to yield any colonies after G418 selection
in either cell line, probably due to the insertion of the large luciferase sequence into the
replicon. In contrast, introduction of the mutation P89L dramatically improved pe
3a Rluc-neo colony formation efficiency and led to an average of 30 or 50 colonies per
selection in Huh7-Lunet and 1C cells tively (. These data confirm that the
mutation P89L is a genotype 3a adaptive mutation.
To further characterize these stably replicating replicon clones, 12 individual
Rluc-neo replicon colonies and a colony pool from Huh7-Lunet and 1C cells were
isolated and expanded. Luciferase activity was used to assess replication levels in these
stable genotype 3a Rluc on cell lines. As shown in the pooled cell line and
essentially all the isolated clones from either Huh7-Lunet or 1C cells showed comparable
or slightly less (< 5-fold) luciferase activity compared with the highly adapted genotype
l a or lb replicons, suggesting an efficient replication of genotype HCV 3a in cell culture.
The high efficiency of and slight variation in HCV RNA replication among the replicon
clones were further verified by immunohistochemical analysis of NS5A protein
expression (data not shown). Genotypic analyses confirmed the presence of P89L in all
the pools and clonal cells. Additional mutations such as A166K or K583E in viral NS3
protein were identified but were not necessary for replication and only ed in half of
ed clones (Table 8). Put together, these data demonstrate that a P89L tution in
NS3 protease domain significantly stimulates genotype 3a HCV replication and allows
establishment of stably replicating luciferase-encoding genotype 3a replicons.
Table 8. Mutations fied in GT3a-P89L-Rluc-neo replicon cells lines
GT3 a-Rluc-Neo-P89L-L 10 P89L - - -
GT3a-Rluc-Neo-P89L-Ll 1 P89L/K583E - - -
GT3 a-Rluc-Neo-P89L-L 1 P89LA379T - - -
Generation of transient-transfection replicating luciferase-encoding
genotype 3a replicons. To facilitate measurement of replication efficiency and kinetics
of pe 3a replicon in ral activity assays and clinical resistance studies, the
eo gene in the parental GT3a-Rluc-Neo replicon construct () was replaced
with a ronic replicon encoding the Rluc reporter gene downstream of the poliovirus
IRES (). Following transfection of luc-Neo-P89L and Pi-Rluc-GT3a-
P89L into 1C cells, luciferase activity was measured post transfection at 4 hours and daily
for 7 days. As shown in luciferase activity of the Rluc-Neo-GT3a-P89L replicon
continuously decreased to a level slightly above the background (~ 100 relative
luminescence units (RLU)), suggesting the replicon did not replicate efficiently in the
transient assay, likely due to ion of the large-size Rluc-Neo gene. Pi-Rluc-GT3a-
P89L conferred a meaningfully higher level of replication. After an initial dip in
luciferase activity over the first 2 days post transfection due to input RNA degradation,
HCV RNA replication reached a level that was two orders of magnitude higher than that
achieved with Rluc-Neo-GT3a-P89L. These results indicate that the Pi-Rluc-GT3a-P89L
replicon is a useful tool to e the ation ency and cs of a genotype
3a replicon.
Using the transient-transfection tool, we determined whether the mutation
S2210I (equivalent to S2204I in genotype 1) in viral NS5A protein is necessary for
genotype 3a RNA replication in combination with P89L. The mutation S2210I in the Pi-
Rluc-GT3a-P89L replicon was reverted by substituting isoluecine with serine, and the
resulting replicon construct was transfected into 1C cells. In the absence of S2210I,
replicon viral RNA levels did not increase, and the replicon did not replicate during 7
days post transfection (. This result indicates that the NS5A mutation S2210I is
required by the ve mutation P89L to t efficient genotype 3a replicon
replication.
Establishment of highly permissive cell lines to improve genotype 3a HCV
RNA replication. Although replication of Pi-Rluc-GT3a-P89L can be readily measured
in a transient transfection assay, it is not robust enough for the high-throughput assays
used for drug ery and development research. Two approaches were taken to further
improve replication efficiency. The first approach was to establish more permissive cell
lines to support genotype 3 R A replication. We cured the three stable clones selected
with the parental genotype 3a neo replicon (Table 5) and speculated that these clonal cells
might be unique to genotype 3a replication because of the low frequency of selection.
The three replicon cell lines (Table 6) were cured using a high-dose cocktail of IFN and
three direct antivirals for 4 weeks. The resulting cured cell lines, designated 3a-Cl, 3a-
C2, and 3a-C3, lacked detectable HCV replication. To assess the ability of the cured cell
lines to support genotype 3a replication, they were transfected with the Pi-Rluc-GT3a-
P89L replicon, and luciferase activity was measured daily for 4 days. Importantly, two
cured replicon , 3a-C2 and 3a-C3 but not 3a-Cl, exhibited imately 10-fold
higher permissiveness to genotype 3a replication than 1C cells (A). To ine
whether the cured cell lines also showed higher permissiveness to other HCV genotype
replication, genotype l a and lb replicons were transfected into 1C and the 3a-C3 cell
lines. Interestingly, there was no notable difference of genotype l a and lb replicon
replication between 1C cells and the cured cell line (B). These results thus
indicated that cell lines, like 3a-C3 cell, was successfully established that could support
significantly higher ation, specifically to genotype 3 HCV.
Characterization of secondary adaptive mutations to improve genotype 3a
HCV RNA replication. The second approach was to fy secondary ve
mutations that further augmented genotype 3 HCV replication. A number of additional
mutations were identified in combination with P89L (summarized in Tables 7 and 8). To
determine whether those mutations could further enhance P89L-dependent HCV RNA
replication, 6 individual mutations that emerged at least twice in those stable clones were
selected and uced into Pi-Rluc-GT3a-P89L by site-directed mutagenesis (Table 9).
Two mutations, Q41R and A166T, were located at the NS3 protease domain, three
mutations were located at A379T, S534G, and K583E at the NS3 helicase domain, and
SIC was located at the NS4A protein. All of the additional mutations further ted
genotype 3a HCV RNA ation compared with P89L alone (A). For example,
the P89L/A166T double mutation replicon ed a peak replication level that was 19
times greater than the P89L single mutation on. rmore, when the
P89L/A166T or P89L/K583E double mutation replicon was ected into genotype 3apermissive
3a-C3 cells, the replicon replication efficiency was further stimulated about 5-
fold to a level that is comparable to the highly adapted genotype l a or lb replicons (B). Put er, a combination of selected host cells (e.g. 3a-C3 cells) and secondary
adaptive mutation (e.g. A166T in NS3) established an efficient system to support
genotype 3 HCV replication in cell culture that is able to those for genotype 1.
Table 9. Mutations analyzed in Rluc-neo-GT3a-P89L replicon cells lines
Evaluation of the antiviral activities of HCV inhibitors against genotype 3a.
To investigate antiviral activity against genotype 3a, five different classes of HCV
inhibitors were tested in a transient assay of the genotype 3a c replicon: NS3
protease, NS5A, NS5B active site, NS5B non-active site, and host factor inhibitors. A
standard genotype lb c replicon was tested in parallel. The transient replicon
ation assays were performed in 1C cells to minimize the potential influence of host
cell difference on compound antiviral ties. EC50 values against both genotype lb
and genotype 3a replicons were successfully generated for all tors using a highthroughput
384-well assay measuring Rluc activity (Table 10).
Table 10. Antiviral ties of HCV tors against genotype l b and 3a replicons
Pi-Rluc-GT3a- i - l -G a-
PS9L/A166T i P89L/K583E Pi-Rluc-GTlb GT3a(P 9L A166T b GT3a(P89L/K583E)ab
Inhibitor Classes Compounds EC50 (nM EC50 (nM) EC50 (nM) EC50 Ratio EC50 Ratio
Telaprevir 650 1330 407 1.6 3.27
460 273 188 2.44 1.45
NS3 Protease GS-9451 1647 10 173 97
M -5 72 m 23 0.81 74 28
BILN-20!i1 447 95 0.93 478 102
GS-5885 92 40 0.0041 22170 9758
S- 0.3 1 0.45 0.03 11 1
GS-7977 12 5.8 40 0.31 0.15
NS5B NIK:
2-C efi 23 15 86 0.27 0.17
GS-9669 230 125 3.8 8 1 33
MK-3281 277 180 587 0.47 0.31
NS5B t GS-9 190 42 46
F ii r 2041 895 121 17 7.4
HCV-796 2.8 2.4 20 0.14 0.12
CsA 111 62 1 1.37 0.76
H Target
SCY-635 78 59 65 1.2 0.91
Five different classes of HCV inhibitors as listed in the first column were evaluated for their
antiviral activities against GTlb and GT3a Pi-Rluc on in a ent transfection high-
throughput 384-well format by measuring renilla luciferase activity. Data presented in the table
represent the mean of at least two independent experiments.
Inhibitors targeting host factors (CsA and SCY-635) had equivalent potency
against both pe l b and 3a replicons. Inhibitors targeting the NS5B active site (2-
CMeA or GS-7977) were 3- to 6-fold more active against genotype 3a compared with lb.
Antivirals that target non-active sites on NS5B polymerase, the NS5B thumb site I
inhibitor 1 and the palm site II NS5B inhibitor 6, were about 2-fold and
7-fold, tively, more active against genotype 3a compared with genotype lb. In
contrast, the NS5B thumb site II inhibitors filibuvir and GS-9669 and the palm site 1/2
inhibitor 0 were approximately 17-, 60-, and 17-fold, respectively, less active
against genotype 3a, versus genotype lb. Although the NS5A inhibitor BMS-790052 was
11-fold less active against genotype 3a, it was still quite potent with E C 50 values of 0.3 1-
0.45 nM against genotype 3a. r NS5A inhibitor, GS-5885 (available from Gilead
Sciences, Inc. Foster City, CA), was imately 10,000-fold less active against
genotype 3a compared with genotype l b (EC 50 values for genotype 3a: 40-92 nM). The
NS3 protease inhibitors boceprevir and telaprevir were slightly less potent ( 1.5- to 3.3-
fold) against genotype 3a versus genotype lb. However, the protease inhibitors BILN-
2061, GS-9451, and MK-5127 were 28- to 478-fold less potent against genotype 3a
versus genotype lb. l, these results demonstrate that the ent transfection of a
genotype 3a replicon system is robust and can serve as a valuable tool for drug discovery,
lead compound optimization, and clinical virology applications.
It will be appreciated that those skilled in the art will be able to devise various
arrangements which, gh not explicitly described or shown herein, embody the
ples of the disclosure and are included within its spirit and scope. Furthermore, all
conditional language recited herein is principally intended to aid the reader in
understanding the principles of the disclosure and the concepts contributed by the
inventors to furthering the art, and are to be construed as being without limitation to such
specifically recited conditions. Moreover, all statements herein reciting principles,
aspects, and embodiments of the disclosure are intended to encompass both structural and
functional lents thereof. Additionally, it is intended that such equivalents include
both currently known equivalents and equivalents developed in the future, i.e., any
elements developed that perform the same function, regardless of structure. The scope of
the t disclosure, therefore, is not intended to be limited to the exemplary
embodiments shown and described herein. Rather, the scope and spirit of present
sure is embodied by the ed claims.
lOOl321151
Claims (34)
1. A genotype 3a hepatitis C Viral (HCV) RNA construct comprising a 5 ‘NTR, an internal ribosome entry site (IRES), sequences encoding NS3 and one or more ofNS4A, NS4B, NSSA or NSSB, and a 3’NTR, wherein the RNA construct r ses a mutation, as compared to a wild-type HCV 3a sequence, wherein the mutation is ed from N607S or P89L or both in N83.
2. The RNA construct of claim 1, wherein the RNA construct comprises the mutation N607S in N83.
3. The RNA construct of claim 1 or 2, wherein the RNA construct comprises the 10 mutation P89L in N83.
4. The RNA construct of claim 3, wherein the construct further comprises a mutation ed from Q41R, Al66T, A379T, SS34G, and K583E in N83 or 81C in NS4A.
5. The RNA uct of any one of the preceding claims, wherein the construct further comprises a mutation $2321 in NSSA. 15
6. The RNA construct of any one of the preceding claims, further comprising a marker gene for selection.
7. The RNA construct of claim 6, wherein the marker gene is a in phosphotransferase gene.
8. The RNA construct of any one of the preceding claims, further comprising a 20 reporter gene.
9. The RNA construct of claim 8, wherein the reporter gene is luciferase.
10. The RNA construct of any one of the preceding claims, wherein the construct comprises, from 5’ to 3’, the S’NTR, the IRES, ces encoding NS3, NS4A, NS4B, NSSA and NSSB, and the 3’NTR. 1001321151
11. The RNA construct of any one of the ing claims, further comprising a sequence encoding one or more of C, E1 or E2.
12. A single or double-stranded DNA that can be transcribed to a RNA construct of any one of claims 1 to 11.
13. A Viral le comprising a RNA construct of any one of claims 1 to 11.
14. An isolated cell comprising a RNA uct of any one of claims 1 to 11 or DNA of claim 12.
15. An N83 protein of HCV genotype 3a that comprises a N6078 mutation as compared to the Wild—type HCV 3a N83 protein. 10
16. An N83 n ofHCV genotype 3a that comprises a P89L mutation as compared to the wild—type HCV 3a N83 protein.
17. The N83 protein of claim 15 or 16, further comprising a mutation selected from Q41R, A166T, A379T, 8534G, or K583E.
18. A polynucleotide encoding the protein of any one of claims 15 to 17. 15
19. The polynucleotide of claim 18, wherein the polynucleotide is RNA or DNA.
20. An RNA or DNA construct comprising the polynucleotide of claim 18 or 19.
21. An isolated cell comprising a polynucleotide of claim 18 or 19, or an RNA or DNA construct of claim 20.
22. An antibody that specifically recognizes a n of any one of claims 15 to 17. 20
23. An isolated cell comprising a genotype 3a HCV RNA construct of any one of claims 1 to 11, n the RNA construct replicates in the cell. 1001321151
24. The cell of claim 23, wherein there is an absence, in the cell, of a DNA uct encoding the RNA.
25. The cell of claim 23 or 24, wherein the cell comprises at least 10 copies of the RNA.
26. The cell of any one of claims 23 to 25, n the cell is a mammalian cell.
27. The cell of claim 26, wherein the cell is a hepatoma cell.
28. The cell of claim 27, n the cell is a Huh7 1C cell.
29. A method of identifying an agent that inhibits the replication or activity of a genotype 3 HCV, comprising contacting a cell of any one of claims 23 to 28 with a candidate 10 agent, wherein a decrease of replication or a decrease of the activity of a protein encoded by the RNA indicates that the agent inhibits the replication or activity of the HCV.
30. A method of identifying an agent that inhibits the activity of a genotype 3 HCV, comprising contacting the lysate of a cell of any one of claims 23 to 28 with a candidate agent, wherein a decrease of the activity of a protein encoded by the RNA indicates that the agent 15 inhibits the activity of the HCV.
31. The method of claim 29 or 30, wherein the protein is a protease.
32. The method of claim 31, r comprising measuring the ation of the RNA or the activity of the protein encoded by the RNA.
33. The genotype 3a HCV RNA construct of claim 1, substantially as hereinbefore 20 described.
34. The N83 protein of HCV genotype 3a of claim 15 or 16, substantially as hereinbefore described.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161504853P | 2011-07-06 | 2011-07-06 | |
US61/504,853 | 2011-07-06 | ||
US201161509989P | 2011-07-20 | 2011-07-20 | |
US61/509,989 | 2011-07-20 | ||
PCT/US2012/045593 WO2013006722A1 (en) | 2011-07-06 | 2012-07-05 | Hcv genotype 3 replicons |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ619298A NZ619298A (en) | 2016-02-26 |
NZ619298B2 true NZ619298B2 (en) | 2016-05-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Infection of common marmosets with hepatitis C virus/GB virus‐B chimeras | |
US9353423B2 (en) | HCV genotype 6 replicons | |
EP1694694B1 (en) | Replication competent hepatitis c virus and methods of use | |
US20160244729A1 (en) | Novel hcv culture systems and direct-acting antiviral sensitivity | |
US9057048B2 (en) | Infectious hepatitis C virus—high producing HCV variants and use thereof | |
AU2012278960B2 (en) | HCV genotype 3 replicons | |
US7655406B2 (en) | Nucleotide sequences coding for the non-structural proteins of the hepatitis C virus | |
AU2012278959B2 (en) | HCV genotype 4 replicons | |
EP3027740B1 (en) | High-titer hcv full-length genotype 2b infectious cell culture systems and applications thereof | |
US20150072418A1 (en) | Hcv genotype 4d replicons | |
NZ619298B2 (en) | Hcv genotype 3 replicons | |
NZ619294B2 (en) | Hcv genotype 4 replicons |